@NP	Autologous olfactory mucosal cell transplants	1
@NP	clinical spinal cord injury	50
@NP	a	79
@NP	double-blinded trial in a canine translational model Nicolas Granger	92
@NP	double-blinded trial	92
@NP	a canine translational model Nicolas Granger	116
@NP	,1 , * Helen Blamires ,1 Robin J.	160
@NP	,1	160
@NP	Helen Blamires ,1	165
@NP	Helen Blamires	165
@NP	,1	179
@NP	Robin J.	182
@NP	M.	191
@NP	Franklin1 ,2 and Nick D.	194
@NP	Franklin1	194
@NP	,2 and Nick D.	203
@NP	,2	203
@NP	Nick D.	210
@NP	Jeffery1 1 Department	218
@NP	Veterinary Medicine	243
@NP	Cambridge , Cambridge , CB3 0ES , UK 2	278
@NP	Cambridge , Cambridge , CB3 0ES	278
@NP	UK 2	309
@NP	University of Cambridge , UK * Present address	345
@NP	University of Cambridge , UK *	345
@NP	University	345
@NP	Cambridge , UK	359
@NP	Present address	374
@NP	School of Veterinary Sciences	391
@NP	School	391
@NP	Veterinary Sciences	401
@NP	University	422
@NP	Bristol	436
@NP	Langford House	445
@NP	Langford	461
@NP	North Somerset	471
@NP	BS40 5DU	487
@NP	UK Correspondence	497
@NP	Nick D.	519
@NP	Jeffery , Department of Veterinary Clinical Sciences	527
@NP	Jeffery , Department	527
@NP	Veterinary Clinical Sciences	550
@NP	College of Veterinary Medicine , Iowa State University ,	580
@NP	College	580
@NP	Veterinary Medicine , Iowa State University ,	591
@NP	Veterinary Medicine	591
@NP	Iowa State University	612
@NP	1600	635
@NP	South 16th Street , Ames , IA 50011 , USA	640
@NP	South 16th Street	640
@NP	Ames	659
@NP	IA 50011	665
@NP	USA	675
@NP	This study	681
@NP	an intervention	726
@NP	the laboratory to ameliorate the effects of experimental spinal cord injury	762
@NP	the effects of experimental spinal cord injury	791
@NP	the effects	791
@NP	experimental spinal cord injury	806
@NP	sufficient benefit	852
@NP	value	880
@NP	clinical cases	889
@NP	Intraspinal olfactory ensheathing cell transplantation	905
@NP	Intraspinal olfactory ensheathing	905
@NP	cell transplantation	939
@NP	locomotor outcome	969
@NP	spinal cord injury in ` proof of principle '	993
@NP	spinal cord injury	993
@NP	proof of principle	1016
@NP	proof	1016
@NP	principle	1025
@NP	experiments in rodents	1036
@NP	experiments	1036
@NP	rodents	1051
@NP	the possibility of efficacy	1071
@NP	the possibility	1071
@NP	efficacy	1090
@NP	human patients	1102
@NP	laboratory animal spinal cord injury	1127
@NP	laboratory animal	1127
@NP	spinal cord injury	1145
@NP	the inherent heterogeneity of clinical patient cohorts	1188
@NP	the inherent heterogeneity	1188
@NP	clinical patient cohorts	1218
@NP	all aspects	1252
@NP	their spinal cord function readily amenable to objective evaluation	1267
@NP	their spinal cord function	1267
@NP	objective evaluation	1314
@NP	we	1342
@NP	the effects	1354
@NP	intraspinal transplantation	1369
@NP	cells	1400
@NP	olfactory mucosal cultures	1419
@NP	a mean of ≈ 50 % olfactory ensheathing cells	1458
@NP	a mean	1458
@NP	≈ 50 % olfactory ensheathing cells	1468
@NP	a population of spinal cord	1505
@NP	a population	1505
@NP	spinal cord	1521
@NP	injured companion dogs	1533
@NP	many of the potential obstacles involved in transition from laboratory to clinic	1578
@NP	many	1578
@NP	the potential obstacles involved in transition from laboratory to clinic	1586
@NP	the potential obstacles	1586
@NP	transition	1622
@NP	laboratory	1638
@NP	clinic	1652
@NP	Dogs	1660
@NP	severe chronic thoracolumbar spinal cord injuries	1670
@NP	equivalent to ASIA grade ` A ' human patients at ≈ 12 months after injury	1721
@NP	equivalent to ASIA grade ` A ' human patients at ≈ 12 months	1721
@NP	ASIA grade	1735
@NP	` A	1746
@NP	human patients	1750
@NP	≈ 12 months	1768
@NP	injury	1785
@NP	a	1811
@NP	double-blinded clinical trial	1824
@NP	they	1863
@NP	intraspinal autologous cells	1901
@NP	olfactory mucosal cultures or injection of cell transport medium	1943
@NP	olfactory mucosal cultures	1943
@NP	injection of cell transport medium	1973
@NP	injection	1973
@NP	cell transport medium	1986
@NP	Recipients of olfactory mucosal cell transplants	2015
@NP	Recipients	2015
@NP	olfactory mucosal cell transplants	2029
@NP	significantly better fore	2071
@NP	hind coordination than those dogs receiving cell transport medium alone	2097
@NP	hind coordination	2097
@NP	those dogs receiving cell transport medium alone	2120
@NP	those dogs	2120
@NP	cell transport medium	2141
@NP	There	2170
@NP	no significant differences	2181
@NP	outcome between treatment groups in measures of long tract functionality	2211
@NP	outcome	2211
@NP	treatment groups in measures of long tract functionality	2227
@NP	treatment groups	2227
@NP	measures of long tract functionality	2247
@NP	measures	2247
@NP	long tract functionality	2259
@NP	We	2285
@NP	intraspinal olfactory mucosal cell transplantation	2302
@NP	communication	2362
@NP	the damaged region of the injured spinal cord	2383
@NP	the damaged region	2383
@NP	the injured spinal cord	2405
@NP	chronically injured individuals	2438
@NP	we	2480
@NP	no evidence for concomitant improvement in long tract function	2488
@NP	no evidence	2488
@NP	concomitant improvement in long tract function	2504
@NP	concomitant improvement	2504
@NP	long tract function	2531
@NP	Introduction Spinal cord injury	2553
@NP	Introduction	2553
@NP	Spinal cord injury	2566
@NP	a devastating impact	2589
@NP	the emotional and physical well-being of affected individuals	2613
@NP	the emotional and physical well-being	2613
@NP	affected individuals	2654
@NP	a substantial financial burden	2687
@NP	providers	2721
@NP	long-term health care	2734
@NP	-LRB- National Spinal Cord Injury Center , https://www.nscisc.uab	2756
@NP	-LRB- National Spinal Cord Injury Center	2756
@NP	https://www.nscisc.uab	2793
@NP	edu	2817
@NP	Many interventions	2824
@NP	beneficial effects on outcome	2861
@NP	beneficial effects	2861
@NP	outcome	2883
@NP	spinal cord injury in ` proof of principle ' experiments in laboratory animals	2897
@NP	spinal cord injury	2897
@NP	` proof of principle ' experiments in laboratory animals	2919
@NP	` proof of principle '	2919
@NP	proof	2920
@NP	principle	2929
@NP	experiments in laboratory animals	2940
@NP	experiments	2940
@NP	laboratory animals	2955
@NP	pharmacological and biological agents	2985
@NP	Kwon	3024
@NP	et al. , 2011a , b ; Tetzlaff et al. , 2011	3029
@NP	et al.	3029
@NP	2011a , b ; Tetzlaff et al.	3037
@NP	2011a , b	3037
@NP	2011a	3037
@NP	b	3044
@NP	Tetzlaff et al.	3047
@NP	Tetzlaff	3047
@NP	et al.	3056
@NP	2011	3064
@NP	training -LRB- Edgerton et al. , 2008 -RRB-	3071
@NP	training	3071
@NP	Edgerton	3081
@NP	et al. , 2008	3090
@NP	et al.	3090
@NP	2008	3098
@NP	rehabilitation -LRB- Wang et al. , 2011 -RRB- strategies	3108
@NP	rehabilitation	3108
@NP	Wang	3124
@NP	et al. , 2011	3129
@NP	et al.	3129
@NP	2011	3137
@NP	strategies	3143
@NP	these	3158
@NP	intraspinal transplantation of olfactory ensheathing cell	3165
@NP	intraspinal transplantation	3165
@NP	olfactory ensheathing cell	3196
@NP	one	3226
@NP	the most promising	3233
@NP	Ibrahim	3253
@NP	et al. , 2006 ; Ramon-Cueto and Mun˜ oz-Quiles , 2011	3261
@NP	et al.	3261
@NP	2006 ; Ramon-Cueto and Mun˜ oz-Quiles	3269
@NP	2006	3269
@NP	Ramon-Cueto and Mun˜ oz-Quiles	3275
@NP	Ramon-Cueto	3275
@NP	Mun˜ oz-Quiles	3291
@NP	2011	3307
@NP	experimental models of spinal cord injury	3332
@NP	experimental models	3332
@NP	spinal cord injury	3355
@NP	new therapies	3398
@NP	success in laboratory animals	3413
@NP	success	3413
@NP	laboratory animals	3424
@NP	benefit for patients	3479
@NP	benefit	3479
@NP	patients	3491
@NP	the many differences between models and clinical disease	3511
@NP	the many differences	3511
@NP	models and clinical disease	3540
@NP	models	3540
@NP	clinical disease	3551
@NP	most human patients	3578
@NP	candidates for transplantation therapy	3606
@NP	candidates	3606
@NP	transplantation therapy	3621
@NP	a variable , and often considerable , delay from initial injury	3651
@NP	a variable , and often considerable , delay	3651
@NP	initial injury	3698
@NP	there	3724
@NP	far greater heterogeneity	3733
@NP	even a	3766
@NP	patient cohort	3782
@NP	a typical experimental group	3809
@NP	purpose-bred rodents	3841
@NP	similar age , mass , injury severity and genetic background	3865
@NP	similar age	3865
@NP	mass	3878
@NP	injury severity	3884
@NP	genetic background	3904
@NP	obscure detection of the effect of interest	3943
@NP	obscure detection	3943
@NP	the effect of interest	3964
@NP	the effect	3964
@NP	interest	3978
@NP	the magnitude of the treatment effect , even if statistically detectable ,	3997
@NP	the magnitude	3997
@NP	the treatment effect	4014
@NP	sufficient magnitude	4084
@NP	patients	4136
@NP	The potential of these factors to obstruct effective translation	4146
@NP	The potential	4146
@NP	these factors	4163
@NP	effective translation	4189
@NP	attention	4244
@NP	other fields	4257
@NP	medicine -LRB- Lowenstein and Castro , 2009 ; Begley and Ellis , 2012 -RRB-	4273
@NP	medicine	4273
@NP	Lowenstein and Castro	4283
@NP	Lowenstein	4283
@NP	Castro	4298
@NP	2009 ; Begley and Ellis , 2012	4306
@NP	2009	4306
@NP	Begley and Ellis , 2012	4312
@NP	Begley and Ellis	4312
@NP	2012	4330
@NP	conventional laboratory models	4374
@NP	Spinal cord injury	4406
@NP	a common condition in companion dogs	4428
@NP	a common condition	4428
@NP	companion dogs	4450
@NP	the high prevalence of intervertebral disc degeneration	4476
@NP	the high prevalence	4476
@NP	intervertebral disc degeneration	4499
@NP	acute nuclear herniation	4536
@NP	Priester , 1976 ; Fluehmann et al. , 2006	4562
@NP	Priester	4562
@NP	1976 ; Fluehmann et al.	4572
@NP	1976	4572
@NP	Fluehmann et al.	4578
@NP	Fluehmann	4578
@NP	et al.	4588
@NP	2006	4596
@NP	a large population	4616
@NP	the effects of putative therapeutic interventions	4644
@NP	the effects	4644
@NP	putative therapeutic interventions	4659
@NP	These dogs	4709
@NP	specialist veterinarians	4749
@NP	similar methods	4780
@NP	those currently available in human patients with spinal cord injury	4799
@NP	human patients with spinal cord	4828
@NP	human patients	4828
@NP	spinal cord	4848
@NP	a clinical trial of a putative therapy for spinal cord injury in dogs	4879
@NP	a clinical trial	4879
@NP	a putative therapy for spinal cord injury in dogs	4899
@NP	a putative therapy	4899
@NP	spinal cord injury in dogs	4922
@NP	spinal cord injury	4922
@NP	dogs	4944
@NP	we	4950
@NP	a series of kinematic outcome measures	4968
@NP	a series	4968
@NP	kinematic outcome measures	4980
@NP	the effect	5031
@NP	an intervention on locomotor function -LRB- Hamilton et al. , 2007 , 2008 -RRB-	5045
@NP	an intervention	5045
@NP	locomotor function -LRB- Hamilton et al. , 2007 , 2008 -RRB-	5064
@NP	locomotor function	5064
@NP	Hamilton	5084
@NP	et al. , 2007 , 2008	5093
@NP	et al.	5093
@NP	2007	5101
@NP	2008	5107
@NP	Objective quantification of gait coordination in dogs	5114
@NP	Objective quantification	5114
@NP	gait coordination in dogs	5142
@NP	gait coordination	5142
@NP	dogs	5163
@NP	their quadrupedal gait	5186
@NP	it	5217
@NP	analysis	5227
@NP	the temporal relationships of motion between thoracic and pelvic limbs	5239
@NP	the temporal relationships	5239
@NP	motion between thoracic and pelvic limbs	5269
@NP	motion	5269
@NP	thoracic and pelvic limbs	5284
@NP	This study	5311
@NP	the first double-blinded randomized trial	5334
@NP	the efficacy	5379
@NP	intraspinal transplants of cells derived from olfactory mucosa cell cultures	5395
@NP	intraspinal transplants	5395
@NP	cells derived from olfactory mucosa cell cultures	5422
@NP	cells	5422
@NP	olfactory mucosa cell cultures	5441
@NP	≈ 50 % p75 + olfactory ensheathing cells	5484
@NP	≈ 50 % p75	5484
@NP	olfactory ensheathing cells	5495
@NP	clinical spinal cord injury	5527
@NP	a means	5576
@NP	potential obstacles	5595
@NP	a putative therapy	5639
@NP	laboratory	5663
@NP	clinic	5677
@NP	The subjects	5685
@NP	a sample	5703
@NP	dogs	5715
@NP	the chronic phase	5723
@NP	the injury	5744
@NP	the large population	5770
@NP	client-owned -LRB- i.e. non-experimental -RRB- dogs	5794
@NP	i.e. non-experimental	5808
@NP	i.e.	5808
@NP	non-experimental	5813
@NP	previously sustained severe acute spinal cord injury	5845
@NP	This phase	5899
@NP	their established poor prognosis -LRB- Olby et al. , 2003 -RRB-	5929
@NP	their established poor prognosis	5929
@NP	Olby	5963
@NP	et al. , 2003	5968
@NP	et al.	5968
@NP	2003	5976
@NP	the efficiency of detection of benefits -LRB- Fawcett et al. , 2007 -RRB-	6000
@NP	the efficiency	6000
@NP	detection of benefits -LRB- Fawcett et al. , 2007 -RRB-	6018
@NP	detection	6018
@NP	benefits -LRB- Fawcett et al. , 2007 -RRB-	6031
@NP	benefits	6031
@NP	Fawcett	6041
@NP	et al. , 2007	6049
@NP	et al.	6049
@NP	2007	6057
@NP	The effects of intraspinal autologous olfactory mucosal cell transplantation	6064
@NP	The effects	6064
@NP	intraspinal autologous olfactory mucosal cell transplantation	6079
@NP	injection of cell transport medium	6160
@NP	injection	6160
@NP	cell transport medium	6173
@NP	a primary outcome measure of forelimb	6207
@NP	a primary outcome measure	6207
@NP	forelimb	6236
@NP	hindlimb coordination	6245
@NP	detailed objective analysis of locomotor coordination	6281
@NP	detailed objective analysis	6281
@NP	locomotor coordination	6312
@NP	a series of secondary outcome measures	6336
@NP	a series	6336
@NP	secondary outcome measures	6348
@NP	the aim	6400
@NP	the mechanisms	6423
@NP	olfactory mucosal cell transplants	6447
@NP	an effect	6494
@NP	Materials	6506
@NP	methods Study design	6520
@NP	methods	6520
@NP	Study design	6528
@NP	canine subjects Candidate companion dogs with severe spinal cord injury	6545
@NP	canine subjects	6545
@NP	Candidate companion dogs with severe spinal cord injury	6561
@NP	Candidate companion dogs	6561
@NP	severe spinal cord injury	6591
@NP	this study between October 2008	6636
@NP	this study	6636
@NP	October 2008	6655
@NP	March 2011	6672
@NP	professional contacts	6691
@NP	presentations at veterinary conferences and notices	6714
@NP	presentations	6714
@NP	veterinary conferences and notices	6731
@NP	websites	6769
@NP	inclusion	6783
@NP	we	6794
@NP	dogs	6812
@NP	< 20 kg	6830
@NP	<	6830
@NP	20 kg	6831
@NP	an acute spinal cord injury	6847
@NP	T10 and L4 spinal cord	6891
@NP	the canine spinal cord	6915
@NP	seven lumbar segments	6942
@NP	≈ L5 vertebra	6982
@NP	conscious pain perception	7022
@NP	i.e.	7049
@NP	no behavioural response to intensely noxious stimuli	7054
@NP	no behavioural response	7054
@NP	intensely noxious stimuli	7081
@NP	the hindquarters	7118
@NP	the ability	7140
@NP	the hindlimbs	7170
@NP	i.e. equivalent	7185
@NP	i.e.	7185
@NP	thoracic ASIA	7204
@NP	Spinal Injury Association	7228
@NP	` A	7255
@NP	human patients	7259
@NP	at least 3 months	7277
@NP	the initial injury	7301
@NP	Available literature -LRB- Olby et al. , 2003 ; Fawcett et al. , 2007 -RRB-	7321
@NP	Available literature	7321
@NP	Olby	7343
@NP	et al. , 2003 ; Fawcett et al. , 2007	7348
@NP	et al.	7348
@NP	2003 ; Fawcett et al.	7356
@NP	2003	7356
@NP	Fawcett et al.	7362
@NP	Fawcett	7362
@NP	et al.	7370
@NP	2007	7378
@NP	this time delay	7398
@NP	12 months	7432
@NP	injury in human patients	7448
@NP	injury	7448
@NP	human patients	7458
@NP	We	7474
@NP	the term ` ability	7481
@NP	some dogs	7525
@NP	reflex hindlimb	7548
@NP	treadmill	7580
@NP	overground walking	7603
@NP	complete thoracolumbar spinal cord injury -LRB- Handa et al. , 1986 -RRB-	7628
@NP	complete thoracolumbar spinal cord injury	7628
@NP	Handa	7671
@NP	et al. , 1986	7677
@NP	et al.	7677
@NP	1986	7685
@NP	Trial exclusion criteria	7692
@NP	intercurrent disease	7722
@NP	constant medication	7753
@NP	ill health with a prognosis for survival of < 12 months	7786
@NP	ill health	7786
@NP	a prognosis for survival of < 12 months	7802
@NP	a prognosis	7802
@NP	survival of < 12 months	7818
@NP	survival	7818
@NP	< 12 months	7830
@NP	<	7830
@NP	12 months	7831
@NP	orthopaedic disease that would preclude accurate locomotor assessment	7842
@NP	orthopaedic disease	7842
@NP	accurate locomotor assessment	7882
@NP	unsuitable temperament	7916
@NP	The study	7940
@NP	the regulations	7970
@NP	the Veterinary Surgeons	8003
@NP	Act	8027
@NP	1966	8032
@NP	the interventions	8044
@NP	therapeutic intent	8078
@NP	we	8098
@NP	previous data suggesting an immediate effect after intraspinal injections	8105
@NP	previous data	8105
@NP	an immediate effect	8130
@NP	intraspinal injections	8156
@NP	the study protocol	8185
@NP	the Royal College of Veterinary Surgeons	8233
@NP	the Royal College	8233
@NP	Veterinary Surgeons	8254
@NP	the Ethical Review Committee	8278
@NP	the Department of Veterinary Medicine , University of Cambridge	8310
@NP	the Department	8310
@NP	Veterinary Medicine , University of Cambridge	8328
@NP	Veterinary Medicine	8328
@NP	University of Cambridge	8349
@NP	University	8349
@NP	Cambridge	8363
@NP	the study	8380
@NP	The owner of each dog	8407
@NP	The owner	8407
@NP	each dog	8420
@NP	written consent	8434
@NP	the procedures	8453
@NP	the nature of the study , the comparator groups and the possibility	8492
@NP	the nature	8492
@NP	the study , the comparator groups and the possibility	8506
@NP	the study	8506
@NP	the comparator groups	8517
@NP	the possibility	8543
@NP	neither intervention would have a beneficial effect ; our previous study	8564
@NP	neither intervention	8564
@NP	a beneficial effect ; our previous study	8596
@NP	a beneficial effect	8596
@NP	our previous study	8617
@NP	transplantation of olfactory bulb-derived cell cultures	8655
@NP	transplantation	8655
@NP	olfactory bulb-derived cell cultures	8674
@NP	dogs -LRB- Jeffery et al. , 2005 -RRB-	8723
@NP	dogs	8723
@NP	Jeffery	8729
@NP	et al. , 2005	8737
@NP	et al.	8737
@NP	2005	8745
@NP	Randomization and masking	8752
@NP	The study	8778
@NP	CONSORT guidelines -LRB- Consolidated Standards of Reporting Trials -RRB-	8815
@NP	CONSORT guidelines	8815
@NP	Consolidated Standards of Reporting Trials	8835
@NP	Consolidated Standards	8835
@NP	Reporting Trials	8861
@NP	Consort	8881
@NP	statement , http : / / www.consort-statement.org/consort-statement/	8889
@NP	statement	8889
@NP	http	8900
@NP	www.consort-statement.org/consort-statement/	8908
@NP	a detailed definition	8965
@NP	primary and secondary outcome measures before trial onset	8990
@NP	primary and secondary outcome measures	8990
@NP	trial onset	9036
@NP	subject flow through the study	9049
@NP	subject flow	9049
@NP	the study	9070
@NP	Fig. 1	9098
@NP	Consecutive patients	9106
@NP	all of the inclusion criteria and none of the exclusion criteria	9135
@NP	all of the inclusion criteria	9135
@NP	all	9135
@NP	the inclusion criteria	9142
@NP	none of the exclusion criteria	9169
@NP	none	9169
@NP	the exclusion criteria	9177
@NP	the study	9217
@NP	preparation of the autologous cell culture for transplantation	9234
@NP	preparation	9234
@NP	the autologous cell culture for transplantation	9249
@NP	the autologous cell culture	9249
@NP	transplantation	9281
@NP	each dog	9298
@NP	spinal needles	9326
@NP	the lesion site -LRB- see later in the text -RRB-	9358
@NP	the lesion site	9358
@NP	the text	9388
@NP	intraspinal injection	9434
@NP	either an olfactory mucosal cell suspension or cell transport medium	9459
@NP	an olfactory mucosal cell suspension	9466
@NP	cell transport medium	9506
@NP	Randomization	9535
@NP	a sealed opaque envelope	9578
@NP	each containing the word ` cells ' or ` medium '	9604
@NP	each	9604
@NP	the word ` cells ' or ` medium '	9620
@NP	word ` cells '	9624
@NP	` medium '	9640
@NP	Three blocks of 18 envelopes	9650
@NP	Three blocks	9650
@NP	18 envelopes	9666
@NP	only two	9703
@NP	time and financial constraints	9732
@NP	each	9765
@NP	which contained 12 envelopes containing ` cells ' and six containing ` medium '	9773
@NP	12 envelopes	9789
@NP	cells	9814
@NP	six containing ` medium '	9825
@NP	six	9825
@NP	medium	9841
@NP	the envelopes	9865
@NP	hand	9896
@NP	a locked drawer	9913
@NP	access	9934
@NP	the unblinded investigator	9959
@NP	N.D.J.	9987
@NP	the different treatments	10012
@NP	We	10038
@NP	a 2:1 ratio	10047
@NP	we	10067
@NP	the cell transplant	10087
@NP	effect on only a proportion of transplanted animals	10118
@NP	effect	10118
@NP	only a proportion of transplanted animals	10128
@NP	only a proportion	10128
@NP	transplanted animals	10149
@NP	Owners	10171
@NP	treatment allocation	10194
@NP	the end of the study period -LRB- 6 months -RRB-	10221
@NP	the end	10221
@NP	the study period -LRB- 6 months -RRB-	10232
@NP	the study period	10232
@NP	6 months	10250
@NP	the clinician and technician responsible for recording the outcome measures	10265
@NP	the clinician and technician	10265
@NP	the outcome measures	10320
@NP	intervention allocation	10357
@NP	completion of data analysis	10387
@NP	completion	10387
@NP	data analysis	10401
@NP	Procedures	10416
@NP	entry to the study	10430
@NP	entry	10430
@NP	the study	10439
@NP	each dog	10450
@NP	a specialist veterinary neurologist -LRB- N.D.J. or N.G. -RRB-	10475
@NP	a specialist veterinary neurologist	10475
@NP	N.D.J. or N.G.	10512
@NP	N.D.J.	10512
@NP	N.G.	10522
@NP	standard T1 - and T2-weighted magnetic resonance	10547
@NP	standard T1	10547
@NP	T2-weighted magnetic resonance	10564
@NP	imaging scanning -LRB- 0.2 Tesla Vet MR , Esaote -RRB-	10595
@NP	imaging scanning	10595
@NP	0.2 Tesla Vet MR , Esaote	10613
@NP	0.2 Tesla Vet MR	10613
@NP	Esaote	10631
@NP	the affected region , treadmill gait recording -LRB- see later in the text -RRB-	10642
@NP	the affected region , treadmill gait recording	10642
@NP	the text	10702
@NP	recording of somatosensory	10713
@NP	recording	10713
@NP	somatosensory	10726
@NP	transcranial magnetic motor-evoked potentials and urodynamics assessment	10745
@NP	receipt of the randomly allocated treatment -LRB- given at time = 0 -RRB-	10825
@NP	receipt	10825
@NP	the randomly allocated treatment -LRB- given at time = 0 -RRB-	10836
@NP	the randomly allocated treatment	10836
@NP	time = 0	10879
@NP	time	10879
@NP	0	10886
@NP	Gait analysis Gait analysis	10890
@NP	Gait analysis	10890
@NP	Gait analysis	10904
@NP	as previously described -LRB- Hamilton et al. , 2007 , 2008 -RRB-	10934
@NP	as previously described	10934
@NP	as previously	10934
@NP	Hamilton	10959
@NP	et al. , 2007 , 2008	10968
@NP	et al.	10968
@NP	2007	10976
@NP	2008	10982
@NP	dogs	10998
@NP	a treadmill	11013
@NP	retroflective markers	11030
@NP	prominent bone landmarks on forelimbs and hindlimbs	11062
@NP	prominent bone landmarks	11062
@NP	forelimbs and hindlimbs	11090
@NP	recordings	11120
@NP	limb motion	11144
@NP	gait analysis equipment -LRB- Qualisys -RRB-	11162
@NP	gait analysis equipment	11162
@NP	Qualisys	11187
@NP	Digital data	11198
@NP	MATLAB software	11239
@NP	extract points of interest	11258
@NP	extract points	11258
@NP	interest	11276
@NP	i	11299
@NP	coordination	11302
@NP	hindlimb and forelimb movements	11323
@NP	the sagittal plane	11358
@NP	` fore -- hind coordination '	11390
@NP	fore	11391
@NP	hind coordination	11396
@NP	connectivity	11437
@NP	the lesion site	11457
@NP	ii	11479
@NP	reproducibility of hindlimb paw placement in the lateral plane	11483
@NP	reproducibility	11483
@NP	hindlimb paw placement in the lateral plane	11502
@NP	hindlimb paw placement	11502
@NP	the lateral plane	11528
@NP	the coefficient of variation of the distance between hindlimb paws	11562
@NP	the coefficient	11562
@NP	variation of the distance between hindlimb paws	11581
@NP	variation	11581
@NP	the distance between hindlimb paws	11594
@NP	the distance	11594
@NP	hindlimb paws	11615
@NP	lateral stability	11643
@NP	coordination between hindlimb paws and body position	11684
@NP	coordination	11684
@NP	hindlimb paws and body position	11705
@NP	hindlimb paws	11705
@NP	body position	11723
@NP	it	11746
@NP	a specific treadmill speed	11769
@NP	the reflex	11826
@NP	rhythm of the hindlimbs	11846
@NP	rhythm	11846
@NP	the hindlimbs	11856
@NP	different treadmill speeds	11904
@NP	the voluntary	11955
@NP	rhythm of the forelimbs	11978
@NP	rhythm	11978
@NP	the forelimbs	11988
@NP	we	12002
@NP	locomotion	12014
@NP	two speeds	12028
@NP	analysis of fore -- hind coordination	12044
@NP	analysis of fore	12044
@NP	analysis	12044
@NP	fore	12056
@NP	hind coordination	12061
@NP	we	12080
@NP	only the data	12088
@NP	the speed	12107
@NP	there	12126
@NP	worse coordination	12136
@NP	the potential for ` entrainment '	12176
@NP	the potential	12176
@NP	` entrainment '	12194
@NP	inaccurate data	12219
@NP	The calculated score for comparison	12237
@NP	The calculated score	12237
@NP	comparison	12262
@NP	the temporal relationship	12284
@NP	each hind paw placement	12318
@NP	the contralateral fore paw	12354
@NP	treadmill stepping	12388
@NP	treadmill	12388
@NP	each limb pair	12408
@NP	the mean score determined and entered into statistical analysis	12448
@NP	the mean score	12448
@NP	statistical analysis	12491
@NP	recovery from incomplete spinal cord injury in dogs	12520
@NP	recovery	12520
@NP	incomplete spinal cord injury in dogs	12534
@NP	incomplete spinal cord injury	12534
@NP	dogs	12567
@NP	clinically observable improvement in locomotion	12573
@NP	clinically observable improvement	12573
@NP	locomotion	12610
@NP	gradual recovery	12638
@NP	both fore	12658
@NP	hind coordination and lateral stability	12668
@NP	normal values -LRB- Jeffery et al. , 2011 -RRB-	12716
@NP	normal values	12716
@NP	Jeffery	12731
@NP	et al. , 2011	12739
@NP	et al.	12739
@NP	2011	12747
@NP	Somatosensory-evoked potentials Somatosensory-evoked potentials	12754
@NP	Somatosensory-evoked potentials	12754
@NP	Somatosensory-evoked potentials	12786
@NP	both hindlimbs of each dog	12837
@NP	both hindlimbs	12837
@NP	each dog	12855
@NP	sedation	12870
@NP	standard techniques -LRB- Poncelet et al. , 1993 -RRB-	12885
@NP	standard techniques	12885
@NP	Poncelet	12906
@NP	et al. , 1993	12915
@NP	et al.	12915
@NP	1993	12923
@NP	stimulation of the tibial nerve at the hock -LRB- ankle -RRB-	12932
@NP	stimulation	12932
@NP	the tibial nerve at the hock -LRB- ankle -RRB-	12947
@NP	the tibial nerve	12947
@NP	the hock -LRB- ankle -RRB-	12967
@NP	the hock	12967
@NP	ankle	12977
@NP	the contralateral sensory cortex	13003
@NP	signal averaging -LRB- 256 sweeps -RRB-	13043
@NP	signal averaging	13043
@NP	256 sweeps	13061
@NP	Transcranial magnetic motor-evoked potentials	13074
@NP	Transcranial magnetic motor-evoked potentials	13120
@NP	both hindlimbs of each dog	13185
@NP	both hindlimbs	13185
@NP	each dog	13203
@NP	sedation	13218
@NP	established techniques	13233
@NP	Sylvestre	13257
@NP	et al. , 1993 ; Da Costa et al. , 2006	13267
@NP	et al.	13267
@NP	1993 ; Da Costa et al.	13275
@NP	1993	13275
@NP	Da Costa et al.	13281
@NP	Da Costa	13281
@NP	et al.	13290
@NP	2006	13298
@NP	the single coil stimulator -LRB- Magstim 200 -RRB-	13305
@NP	the single coil stimulator	13305
@NP	Magstim 200	13333
@NP	the motor cortex	13366
@NP	the cranial tibial muscle	13420
@NP	Urodynamics	13447
@NP	sedation	13467
@NP	bladder cystometry with combined rectal pressure measurement recordings	13477
@NP	bladder cystometry	13477
@NP	combined rectal pressure measurement recordings	13501
@NP	conventional urodynamic equipment -LRB- Life-Tech , Urolab Primus 6 -RRB-	13565
@NP	conventional urodynamic equipment	13565
@NP	Life-Tech , Urolab Primus 6	13600
@NP	Life-Tech	13600
@NP	Urolab Primus 6	13611
@NP	Compliance	13629
@NP	the International Continence Society -LRB- Abrams et al. , 2003 -RRB-	13667
@NP	the International Continence Society	13667
@NP	Abrams	13705
@NP	et al. , 2003	13712
@NP	et al.	13712
@NP	2003	13720
@NP	the change	13729
@NP	volume	13743
@NP	the change in pressure at full bladder physiological capacity or first leak	13761
@NP	pressure at full bladder	13775
@NP	pressure	13775
@NP	full bladder	13787
@NP	Cell harvest and culture	13838
@NP	initial gait	13869
@NP	electrophysiological and urodynamic recordings	13883
@NP	each dog	13946
@NP	general anaesthesia	13965
@NP	the left frontal sinus of the skull	13989
@NP	the left frontal sinus	13989
@NP	the skull	14015
@NP	the olfactory mucosa	14058
@NP	the ostium of the frontal sinus	14092
@NP	the ostium	14092
@NP	the frontal sinus	14106
@NP	the caudal nasal cavity -LRB- Skinner et al. , 2005 -RRB-	14128
@NP	the caudal nasal cavity	14128
@NP	Skinner	14153
@NP	et al. , 2005	14161
@NP	et al.	14161
@NP	2005	14169
@NP	The small fragments of obtained olfactory mucosa	14176
@NP	The small fragments	14176
@NP	obtained olfactory mucosa	14199
@NP	20 ml of Leibovitz sterile medium -LRB- L15 -RRB-	14240
@NP	20 ml	14240
@NP	Leibovitz sterile medium -LRB- L15 -RRB-	14249
@NP	Leibovitz sterile medium	14249
@NP	Leibovitz	14249
@NP	L15	14275
@NP	a Petri dish , pre-cooled at 4 °C ,	14283
@NP	a Petri dish	14283
@NP	4 °C	14311
@NP	ice	14324
@NP	the operating room	14349
@NP	the laboratory to be processed	14371
@NP	The mucosal biopsies	14403
@NP	ice	14442
@NP	cartilage fragments , blood vessels , connective tissue and non-olfactory mucosa	14481
@NP	cartilage fragments	14481
@NP	blood vessels	14502
@NP	connective tissue	14517
@NP	non-olfactory mucosa	14539
@NP	The remaining olfactory mucosa	14561
@NP	a scalpel blade for 1 min	14614
@NP	a scalpel blade	14614
@NP	1 min	14634
@NP	15 min	14660
@NP	37 °C	14670
@NP	1 ml of Dulbecco 's modified Eagle medium containing 0.25 mg of 112	14679
@NP	1 ml	14679
@NP	Dulbecco 's modified Eagle medium containing 0.25 mg of 112	14687
@NP	Dulbecco 's modified Eagle medium	14687
@NP	Dulbecco 's	14687
@NP	0.25 mg of 112	14731
@NP	0.25 mg	14731
@NP	112	14741
@NP	U collagenase	14745
@NP	incubation	14766
@NP	1 ml	14778
@NP	Dulbecco 's modified Eagle medium containing 0.5 mg of bovine pancreas DNase	14786
@NP	Dulbecco 's modified Eagle medium	14786
@NP	Dulbecco 's	14786
@NP	0.5 mg of bovine pancreas DNase	14830
@NP	0.5 mg	14830
@NP	bovine pancreas DNase	14839
@NP	the tissue	14875
@NP	1 min	14905
@NP	glass pipettes	14919
@NP	40µm filter	14945
@NP	10 ml	14969
@NP	Dulbecco 's modified Eagle medium containing 10 % foetal bovine serum	14975
@NP	Dulbecco 's modified Eagle medium containing 10 %	14975
@NP	Dulbecco 's modified Eagle medium	14975
@NP	Dulbecco 's	14975
@NP	10 %	15019
@NP	foetal bovine serum	15023
@NP	1000 rpm , 5 min	15060
@NP	1000 rpm	15060
@NP	5 min	15070
@NP	The pellet	15078
@NP	fresh culture medium	15108
@NP	Dulbecco 's modified Eagle medium	15140
@NP	Dulbecco 's	15140
@NP	10 % foetal bovine serum	15174
@NP	2 µM forskolin	15199
@NP	dimethyl sulphoxide	15217
@NP	20 ng/ml neuregulin 1 and 10 mg/ml gentamicin	15238
@NP	20 ng/ml neuregulin	15238
@NP	1 and 10 mg/ml gentamicin	15258
@NP	10 000 to 50 000 viable cells/ml	15296
@NP	10 000	15296
@NP	50 000 viable cells/ml	15306
@NP	poly-L-lysine	15335
@NP	coated 25-cm2 flasks	15349
@NP	Cultures	15371
@NP	37 °C in 5 % carbon dioxide	15399
@NP	37 °C	15399
@NP	5 % carbon dioxide	15407
@NP	initial plating	15432
@NP	cultures	15449
@NP	5 -- 7 days	15479
@NP	5	15479
@NP	7 days	15481
@NP	cell adhesion	15497
@NP	one half of the growth medium	15524
@NP	one half	15524
@NP	the growth medium	15536
@NP	every 3 days	15566
@NP	cell passaging	15584
@NP	trypsin solution -LRB- 2.5 % in PBS -RRB-	15600
@NP	trypsin solution	15600
@NP	2.5 % in PBS	15618
@NP	2.5 %	15618
@NP	PBS	15626
@NP	the cells	15650
@NP	Cells of interest	15661
@NP	Cells	15661
@NP	interest	15670
@NP	detachment of elongated cells under a microscope	15706
@NP	detachment	15706
@NP	cells	15730
@NP	a microscope	15742
@NP	the trypsin	15768
@NP	this time point -LRB- usually 52 min -RRB-	15783
@NP	this time point	15783
@NP	52 min	15808
@NP	further detachment	15827
@NP	contaminant cells -LRB- i.e. differential trypsinization -RRB-	15849
@NP	contaminant cells	15849
@NP	i.e. differential trypsinization	15868
@NP	i.e.	15868
@NP	differential trypsinization	15873
@NP	The obtained cells	15903
@NP	new uncoated 25-cm2 flasks using the medium described earlier	15937
@NP	new uncoated 25-cm2 flasks	15937
@NP	the medium described earlier	15970
@NP	the medium	15970
@NP	the uncoated flasks	16017
@NP	24 h	16051
@NP	cells , as described previously -LRB- Ito et al. , 2008 -RRB-	16107
@NP	cells , as described previously	16107
@NP	cells	16107
@NP	Ito	16139
@NP	et al. , 2008	16143
@NP	et al.	16143
@NP	2008	16151
@NP	The supernatant	16158
@NP	new poly-L-lysine -- coated 25-cm2 flasks	16188
@NP	new poly-L-lysine	16188
@NP	coated 25-cm2 flasks	16206
@NP	the first 7 -- 10 days in culture	16234
@NP	the first 7	16234
@NP	10 days in culture	16246
@NP	10 days	16246
@NP	culture	16257
@NP	the foetal bovine serum concentration	16266
@NP	10 % to 2.5 %	16331
@NP	7 days	16348
@NP	cellular growth	16369
@NP	a sufficient number of cells	16391
@NP	a sufficient number	16391
@NP	cells	16414
@NP	the cells	16433
@NP	larger -LRB- 75 cm2 and T175 cm2 -RRB- flasks	16458
@NP	75 cm2 and T175 cm2	16466
@NP	75 cm2	16466
@NP	T175 cm2	16477
@NP	the day of transplantation	16498
@NP	the day	16498
@NP	transplantation	16509
@NP	the cell population	16526
@NP	the proportion of p75 + cells and the total population number	16572
@NP	the proportion	16572
@NP	p75 + cells and the total population number	16590
@NP	p75 + cells	16590
@NP	the total population number	16606
@NP	We	16635
@NP	a population of at least 5 x 10 ^ 6 cells	16655
@NP	a population of at least 5	16655
@NP	a population	16655
@NP	at least 5	16671
@NP	10 ^ 6 cells	16684
@NP	10 ^	16684
@NP	6 cells	16687
@NP	at least 2.5	16707
@NP	10 ^ 6 p75	16722
@NP	10 ^	16722
@NP	6 p75	16725
@NP	cells	16733
@NP	i.e.	16740
@NP	those previously	16745
@NP	olfactory ensheathing cells in nasal mucosal cultures	16776
@NP	olfactory ensheathing cells	16776
@NP	nasal mucosal cultures	16807
@NP	Ito	16832
@NP	et al. , 2008	16836
@NP	et al.	16836
@NP	2008	16844
@NP	the time of transplantation	16853
@NP	the time	16853
@NP	transplantation	16865
@NP	the required number of cells	16887
@NP	the required number	16887
@NP	cells	16910
@NP	transplantation	16930
@NP	3 and 5 weeks after harvesting	16955
@NP	3 and 5 weeks	16955
@NP	harvesting	16975
@NP	each dog	16988
@NP	fluoroscopy	17037
@NP	an image intensifier	17056
@NP	a resolution of 441 pixels/cm	17082
@NP	a resolution	17082
@NP	441 pixels/cm	17098
@NP	the centre of the screen	17115
@NP	the centre	17115
@NP	the screen	17129
@NP	placement of 20 -- 22-gauge 90-mm long spinal needles	17150
@NP	placement of 20	17150
@NP	placement	17150
@NP	20	17163
@NP	22-gauge 90-mm long spinal needles	17166
@NP	the interarcuate ligaments between the vertebral laminae	17224
@NP	the interarcuate ligaments	17224
@NP	the vertebral laminae	17259
@NP	the affected region of the spinal cord identified previously by MRI	17286
@NP	the affected region	17286
@NP	the spinal cord identified previously by MRI	17309
@NP	the spinal cord	17309
@NP	MRI	17350
@NP	each dog	17359
@NP	three needles	17369
@NP	one	17396
@NP	the vertebrae	17408
@NP	the epicentre of the lesion and one each	17432
@NP	the epicentre of the lesion	17432
@NP	the epicentre	17432
@NP	the lesion	17449
@NP	one each	17464
@NP	one	17464
@NP	each	17468
@NP	the neighbouring intervertebral spaces	17476
@NP	The needles	17516
@NP	the spinal cord parenchyma	17550
@NP	the ventral aspect of the vertebral canal	17586
@NP	the ventral aspect	17586
@NP	the vertebral canal	17608
@NP	this position	17632
@NP	fluoroscopy	17668
@NP	cerebrospinal fluid	17694
@NP	the needle hub	17728
@NP	some cases	17752
@NP	injections of radiographic contrast agent	17764
@NP	injections	17764
@NP	radiographic contrast agent	17778
@NP	the vertebral canal	17856
@NP	their correct location	17896
@NP	the vertebral canal	17926
@NP	the needles	17947
@NP	a few millimetres	17974
@NP	the needle bevel	18000
@NP	the centre of the vertebral canal	18038
@NP	the centre	18038
@NP	the vertebral canal	18052
@NP	the spinal cord parenchyma	18094
@NP	this stage	18126
@NP	dogs	18138
@NP	a 2:1 ratio of olfactory mucosal cell : medium alone	18163
@NP	a 2:1 ratio	18163
@NP	olfactory mucosal cell	18178
@NP	medium alone	18202
@NP	olfactory mucosal cell in cell transplant medium	18234
@NP	olfactory mucosal cell	18234
@NP	cell transplant medium	18260
@NP	the same volume of cell transport medium	18286
@NP	the same volume	18286
@NP	cell transport medium	18305
@NP	the parenchyma of the spinal cord	18357
@NP	the parenchyma	18357
@NP	the spinal cord	18375
@NP	The injection volume	18392
@NP	400 ml in total , delivered over a period of ≈ 5 min	18417
@NP	400 ml	18417
@NP	total , delivered over a period of ≈ 5 min	18427
@NP	total	18427
@NP	a period of ≈ 5 min	18449
@NP	a period	18449
@NP	≈ 5 min	18461
@NP	200 ml	18469
@NP	the epicentre , divided into two boluses	18488
@NP	the epicentre	18488
@NP	two boluses	18516
@NP	100 µl with the needle bevel	18529
@NP	100 µl	18529
@NP	the needle bevel	18541
@NP	100 µl with the needle bevel	18581
@NP	100 µl	18581
@NP	the needle bevel	18593
@NP	a single bolus of 100 µl at each neighbouring space	18634
@NP	a single bolus	18634
@NP	100 µl at each neighbouring space	18652
@NP	100 µl	18652
@NP	each neighbouring space	18662
@NP	the needle bevel	18692
@NP	the epicentre	18726
@NP	recovery	18744
@NP	each dog	18754
@NP	routine analgesia	18772
@NP	possible adverse effects for 24 h	18811
@NP	possible adverse effects	18811
@NP	24 h	18840
@NP	the owner 's care	18865
@NP	the owner 's	18865
@NP	Outcome measure assessment Each dog	18883
@NP	Outcome measure assessment	18883
@NP	Each dog	18910
@NP	1-monthly intervals for clinical neurological examination	18935
@NP	1-monthly intervals	18935
@NP	clinical neurological examination	18959
@NP	reassessment of locomotor performance	18997
@NP	reassessment	18997
@NP	locomotor performance	19013
@NP	the treadmill	19038
@NP	somatosensory-evoked potential	19053
@NP	transcranial magnetic motor-evoked potential recording	19088
@NP	Urodynamic assessments	19144
@NP	1 , 3 and 6	19180
@NP	months	19191
@NP	spinal cord injection	19204
@NP	Statistical analysis Pre-study power calculations	19227
@NP	responses in a Phase	19286
@NP	responses	19286
@NP	a Phase	19299
@NP	I trial -LRB- Jeffery et al. , 2005 -RRB-	19307
@NP	I trial	19307
@NP	Jeffery	19316
@NP	et al. , 2005	19324
@NP	et al.	19324
@NP	2005	19332
@NP	the need	19348
@NP	54 dogs	19361
@NP	total	19372
@NP	25 % improvement	19389
@NP	a set value	19408
@NP	the olfactory mucosal cell group	19423
@NP	a 0 % improvement in the control group	19463
@NP	a 0 % improvement	19463
@NP	the control group	19483
@NP	80 % power and P	19504
@NP	= 0.05	19520
@NP	a projected n = 48	19537
@NP	a projected n	19537
@NP	48	19553
@NP	Correction for the 2:1 randomization ratio	19557
@NP	Correction	19557
@NP	the 2:1 randomization ratio	19572
@NP	the need	19610
@NP	54 dogs	19623
@NP	total	19634
@NP	we	19655
@NP	numerical measurements of locomotor coordination and analysis	19666
@NP	numerical measurements	19666
@NP	locomotor coordination and analysis	19692
@NP	multivariable linear regression	19731
@NP	analytical efficiency	19780
@NP	all of the repeated-measures data	19806
@NP	all	19806
@NP	the repeated-measures data	19813
@NP	correction	19860
@NP	effect modifiers , confounders and covariates	19875
@NP	importantly here , the baseline values	19921
@NP	importantly here	19921
@NP	the baseline values	19939
@NP	Our pre-specified primary outcome measure	19985
@NP	a summary of fore	20031
@NP	a summary	20031
@NP	fore	20044
@NP	hind coordination	20049
@NP	the mean	20079
@NP	the score	20091
@NP	the ` cumulative lag ' between each hindlimb/contralateral forelimb pair	20113
@NP	the ` cumulative lag '	20113
@NP	each hindlimb/contralateral forelimb pair	20142
@NP	Data	20185
@NP	distributions	20236
@NP	Statistical analysis	20251
@NP	group	20294
@NP	olfactory mucosal cell transplantation versus medium injection	20301
@NP	olfactory mucosal cell transplantation	20301
@NP	medium injection	20347
@NP	visit -LRB- time -RRB-	20375
@NP	visit	20375
@NP	time	20382
@NP	variables	20391
@NP	a random effects model	20404
@NP	multivariable linear regression analysis	20427
@NP	cross-sectional time series data in Stata 11	20472
@NP	cross-sectional time series data	20472
@NP	Stata 11	20508
@NP	command ` xtreg '	20518
@NP	pre-intervention values	20553
@NP	their inclusion as a covariate -LRB- i.e. analysis of covariance -RRB-	20580
@NP	their inclusion	20580
@NP	a covariate -LRB- i.e. analysis of covariance -RRB-	20599
@NP	a covariate	20599
@NP	i.e. analysis of covariance	20612
@NP	i.e.	20612
@NP	analysis of covariance	20617
@NP	analysis	20617
@NP	covariance	20629
@NP	A two-sided P < 0.05	20642
@NP	A two-sided P <	20642
@NP	A two-sided P	20642
@NP	<	20655
@NP	0.05	20656
@NP	evidence	20674
@NP	the null hypothesis	20693
@NP	Pre-specified secondary outcome measures	20714
@NP	lateral stability during treadmill walking -LRB- Hamilton et al. , 2008 -RRB-	20760
@NP	lateral stability	20760
@NP	treadmill walking	20785
@NP	Hamilton	20804
@NP	et al. , 2008	20813
@NP	et al.	20813
@NP	2008	20821
@NP	somatosensory-evoked potential	20828
@NP	transcranial magnetic motor	20860
@NP	potential and bladder compliance	20895
@NP	Use of a kinematic variable as the primary outcome	20929
@NP	Use	20929
@NP	a kinematic variable as the primary outcome	20936
@NP	a kinematic variable	20936
@NP	the primary outcome	20960
@NP	objective data	20989
@NP	rigorous quantitative analysis	21015
@NP	a sense of value of the effect in treated cases	21084
@NP	a sense	21084
@NP	value of the effect in treated cases	21095
@NP	value	21095
@NP	the effect in treated cases	21104
@NP	the effect	21104
@NP	treated cases	21118
@NP	This	21133
@NP	analysis	21163
@NP	the relationship between intervention effect	21175
@NP	the relationship	21175
@NP	intervention effect	21200
@NP	the ` minimal important clinical difference ' or similar score-based schemes	21224
@NP	the ` minimal important clinical difference '	21224
@NP	similar score-based schemes	21271
@NP	Such schemes	21300
@NP	quality-of-life instruments	21345
@NP	they	21381
@NP	a subjective impression	21393
@NP	the objectively measured outcome	21420
@NP	this	21458
@NP	them	21471
@NP	non-verbal species	21491
@NP	distribution-based methods -LRB- Wyrwich and Wolinshy , 2000 -RRB-	21520
@NP	distribution-based methods	21520
@NP	Wyrwich and Wolinshy	21548
@NP	2000	21570
@NP	we	21598
@NP	the magnitude	21612
@NP	the effect	21629
@NP	groups -LRB- δ -RRB- using the formula δ = m2-m1 / σ1 ;	21650
@NP	groups -LRB- δ -RRB-	21650
@NP	groups	21650
@NP	δ	21658
@NP	the formula δ = m2-m1	21667
@NP	σ1	21689
@NP	m2 and m1	21699
@NP	the mean values	21713
@NP	coordination score in the two groups at study termination and Ψδ	21732
@NP	coordination score	21732
@NP	the two groups at study termination and Ψδ	21754
@NP	the two groups	21754
@NP	study termination and Ψδ	21772
@NP	the standard deviation -LRB- SD -RRB- of the whole sample population at baseline	21800
@NP	the standard deviation -LRB- SD -RRB-	21800
@NP	the standard deviation	21800
@NP	SD	21824
@NP	the whole sample population at baseline	21831
@NP	the whole sample population	21831
@NP	baseline	21862
@NP	cell transplant recipients	21884
@NP	we	21912
@NP	the relationship between functional recovery	21924
@NP	the relationship	21924
@NP	functional recovery	21949
@NP	the proportion	21973
@NP	p75 + cells -LRB- assumed to be olfactory ensheathing cells -RRB-	21991
@NP	p75 + cells	21991
@NP	olfactory ensheathing cells	22018
@NP	the transplanted culture	22050
@NP	regression analysis	22081
@NP	pre-transplant score	22124
@NP	inclusion as a covariate	22148
@NP	inclusion	22148
@NP	a covariate	22161
@NP	Results	22175
@NP	Table 1 Baseline animal data	22183
@NP	Table	22183
@NP	1 Baseline animal data	22189
@NP	Table	22213
@NP	2 Baseline values for outcome measures	22219
@NP	2 Baseline values	22219
@NP	outcome measures	22241
@NP	Table 3 Adverse events Figure 1 Flow chart	22259
@NP	patient recruitment , assessment and follow-up	22316
@NP	patient recruitment	22316
@NP	assessment	22337
@NP	follow-up	22352
@NP	OMC = olfactory mucosal cell .	22363
@NP	OMC	22363
@NP	= olfactory mucosal cell	22367
@NP	Figure 2 Flow chart to illustrate trial design .	22394
@NP	Figure 2 Flow chart	22394
@NP	trial design	22428
@NP	-LRB- A -RRB- Trial dogs	22442
@NP	-LRB- A -RRB-	22442
@NP	Trial dogs	22446
@NP	the population	22477
@NP	companion dogs	22495
@NP	severe spinal cord injury at least 3 months	22528
@NP	severe spinal cord injury	22528
@NP	at least 3 months	22554
@NP	behavioural evidence of pain perception	22604
@NP	behavioural evidence	22604
@NP	pain perception	22628
@NP	the hindlimbs or voluntary hindlimb locomotor function or urinary continence	22649
@NP	the hindlimbs	22649
@NP	voluntary hindlimb locomotor function or urinary continence	22666
@NP	voluntary hindlimb locomotor function	22666
@NP	urinary continence	22707
@NP	They	22727
@NP	olfactory mucosal cells -LRB- OMCs -RRB- or cell transport medium	22767
@NP	olfactory mucosal cells	22767
@NP	OMCs	22792
@NP	cell transport medium	22801
@NP	a 2:1 ratio	22832
@NP	-LRB- B -RRB- Olfactory mucosa	22845
@NP	B	22846
@NP	each dog and olfactory mucosal cells	22885
@NP	each dog	22885
@NP	olfactory mucosal cells	22898
@NP	culture	22941
@NP	≈ 3 weeks	22953
@NP	a total population of ≈ 5	22974
@NP	a total population	22974
@NP	≈ 5	22996
@NP	x 10 ^ 6 cells	22999
@NP	≈ 50 % olfactory ensheathing cells	23023
@NP	p75 +	23068
@NP	p75	23068
@NP	+	23072
@NP	immunocytochemistry	23077
@NP	transplantation	23105
@NP	values stated here	23121
@NP	values	23121
@NP	mean ± SEM of the cell population among all 34 dogs	23144
@NP	mean ± SEM	23144
@NP	the cell population among all 34 dogs	23158
@NP	the cell population	23158
@NP	all 34 dogs	23184
@NP	Each dog	23201
@NP	an intraspinal transplant	23219
@NP	either autologous olfactory mucosal cells or cell culture medium	23248
@NP	autologous olfactory mucosal cells	23255
@NP	cell culture medium	23293
@NP	Transplants	23320
@NP	fluoroscopic guidance	23368
@NP	correct needle placement	23400
@NP	-LRB- D -RRB- A blinded observer	23426
@NP	-LRB- D -RRB-	23426
@NP	A blinded observer	23430
@NP	outcome	23458
@NP	monthly intervals for 6 months	23469
@NP	monthly intervals	23469
@NP	6 months	23491
@NP	intervention	23506
@NP	Each test and statistical analysis method	23520
@NP	Each test	23520
@NP	statistical analysis method	23534
@NP	analysis	23596
@NP	the primary outcome measure	23606
@NP	objective quantification of forelimb	23638
@NP	objective quantification	23638
@NP	forelimb	23666
@NP	hindlimb temporal coordination	23675
@NP	computerized analysis of digitized kinematic data	23712
@NP	computerized analysis	23712
@NP	digitized kinematic data	23737
@NP	SSEP = somatosensory-evoked potential	23763
@NP	TMMEP = transcranial magnetic motor-evoked potential	23802
@NP	Figure 3 Digital recordings of locomotor activity	23857
@NP	Figure 3 Digital recordings	23857
@NP	Figure	23857
@NP	3 Digital recordings	23864
@NP	locomotor activity	23888
@NP	sine wave patterns	23929
@NP	forward and backward	23971
@NP	motion of the paws during walking on a treadmill	23992
@NP	motion	23992
@NP	the paws during walking on a treadmill	24002
@NP	the paws	24002
@NP	a treadmill	24029
@NP	this series of wave patterns	24045
@NP	this series	24045
@NP	wave patterns	24060
@NP	video recordings of Dog 8 in Supplementary Fig. 2	24092
@NP	video recordings	24092
@NP	Dog 8 in Supplementary Fig. 2	24112
@NP	Dog 8	24112
@NP	Supplementary Fig. 2	24121
@NP	the fore paw movement	24143
@NP	the dark and light green traces and the hind paw movement	24177
@NP	the dark and light green traces	24177
@NP	the hind paw movement	24213
@NP	the red and blue traces	24238
@NP	The generation of the sine wave pattern	24263
@NP	The generation	24263
@NP	the sine wave pattern	24281
@NP	in A	24318
@NP	the correspondence between forward and backward motion of the paw	24337
@NP	the correspondence between forward	24337
@NP	the correspondence	24337
@NP	backward motion of the paw	24376
@NP	backward motion	24376
@NP	the paw	24395
@NP	treadmill walking -LRB- the oval shape on the image in A -RRB-	24410
@NP	treadmill walking	24410
@NP	the oval shape on the image in A	24429
@NP	the oval shape	24429
@NP	the image in A	24447
@NP	the image	24447
@NP	A	24460
@NP	the wave pattern	24467
@NP	Temporal coordination between forelimb and hindlimb motion	24485
@NP	Temporal coordination	24485
@NP	forelimb and hindlimb motion	24515
@NP	a MATLAB script	24567
@NP	the time interval	24596
@NP	the peaks	24622
@NP	the ` sine wave ' patterns	24635
@NP	red lines between the curves in B , C and D	24661
@NP	red lines	24661
@NP	the curves in B , C and D	24679
@NP	the curves	24679
@NP	B , C and D	24693
@NP	the furthest extent of each step	24723
@NP	the furthest extent	24723
@NP	each step	24746
@NP	each limb	24759
@NP	Pre-transplantation	24770
@NP	Dog 8 -LRB- A -RRB-	24793
@NP	there	24804
@NP	only occasional stepping movements in the hindlimb	24814
@NP	only occasional	24814
@NP	movements in the hindlimb	24839
@NP	movements	24839
@NP	the hindlimb	24852
@NP	this	24869
@NP	the very high ` coordination score ' -LRB- here = 2.71 -RRB-	24890
@NP	the very high ` coordination score '	24890
@NP	= 2.71	24931
@NP	a summation of the ` lag ' between corresponding forelimb and hindlimb movements	24949
@NP	a summation	24949
@NP	the ` lag ' between corresponding forelimb and hindlimb movements	24964
@NP	the ` lag '	24964
@NP	corresponding forelimb and hindlimb movements	24982
@NP	1 month -LRB- B -RRB- and 6 months -LRB- C -RRB-	25032
@NP	1 month -LRB- B -RRB-	25032
@NP	1 month	25032
@NP	B	25041
@NP	6 months -LRB- C -RRB-	25048
@NP	C	25058
@NP	the same dog	25062
@NP	more regular hindlimb stepping	25081
@NP	more regular hindlimb	25081
@NP	overall coordination	25117
@NP	there	25165
@NP	an increasing ` lag ' time	25185
@NP	corresponding fore paw and hind paw placement	25218
@NP	the recording period	25271
@NP	the ` coordination score ' is 1.21 in B and 0.78 in C	25293
@NP	the ` coordination score ' is 1.21 in B	25293
@NP	the ` coordination score '	25293
@NP	1.21 in B	25321
@NP	1.21	25321
@NP	B	25329
@NP	0.78 in C	25335
@NP	0.78	25335
@NP	C	25343
@NP	D	25350
@NP	Dog 30	25353
@NP	a return	25372
@NP	near-normal coordination	25384
@NP	fore paw and hind paw placement	25417
@NP	transplantation of olfactory mucosal cells 6 months	25455
@NP	transplantation	25455
@NP	olfactory mucosal cells	25474
@NP	6 months	25498
@NP	the ` coordination score ' = 0.26	25519
@NP	the ` coordination score '	25519
@NP	= 0.26	25544
@NP	this panel	25556
@NP	there	25568
@NP	prolonged periods	25578
@NP	regularity	25599
@NP	the time interval	25613
@NP	fore paw and hind paw placement	25639
@NP	normal dogs	25685
@NP	periods in which coordination between limb girdles is lost	25716
@NP	periods	25716
@NP	coordination between limb girdles	25733
@NP	coordination	25733
@NP	limb girdles	25754
@NP	Figure 4 Analysis	25777
@NP	effect	25798
@NP	intraspinal injection	25808
@NP	olfactory mucosal cells -LRB- OMC , blue -RRB-	25833
@NP	olfactory mucosal cells	25833
@NP	OMC	25858
@NP	blue	25863
@NP	cell transport medium	25883
@NP	NC , red	25912
@NP	NC	25912
@NP	red	25916
@NP	measures of forelimb	25924
@NP	measures	25924
@NP	forelimb	25936
@NP	hindlimb coordination -LRB- A -RRB-	25945
@NP	hindlimb coordination	25945
@NP	A	25968
@NP	spinal cord long tract function -LRB- B -- E -RRB-	25975
@NP	spinal cord	25975
@NP	long tract function -LRB- B -- E -RRB-	25987
@NP	long tract function	25987
@NP	B -- E	26008
@NP	B	26008
@NP	E	26010
@NP	-LRB- A -RRB- Linear regression plot of fore	26014
@NP	-LRB- A -RRB- Linear regression plot	26014
@NP	-LRB- A -RRB- Linear regression	26014
@NP	A	26015
@NP	fore	26044
@NP	hind coordination scores	26049
@NP	the 6-month trial period -LRB- low scores indicate good performance -RRB-	26081
@NP	the 6-month trial period	26081
@NP	low scores	26107
@NP	good performance	26127
@NP	* The sum effect	26146
@NP	The sum effect	26147
@NP	olfactory mucosal cell transplantation	26165
@NP	the no-cell group	26218
@NP	the effects of time and baseline scores	26258
@NP	the effects	26258
@NP	time and baseline scores	26273
@NP	b	26323
@NP	= -0.455 ; P = 0.007	26325
@NP	= -0.455	26325
@NP	P = 0.007	26335
@NP	P	26335
@NP	0.007	26339
@NP	-LRB- B -RRB- Linear regression	26347
@NP	B	26348
@NP	plot	26369
@NP	lateral stability ratio scores	26377
@NP	the 6-month trial period	26415
@NP	low scores	26441
@NP	poor performance	26461
@NP	The scores	26480
@NP	the olfactory mucosal cell and no-cell groups -LRB- b = 0.049 ; P = 0.428 -RRB-	26514
@NP	the olfactory mucosal cell	26514
@NP	no-cell groups -LRB- b = 0.049 ; P = 0.428 -RRB-	26545
@NP	no-cell groups	26545
@NP	b = 0.049 ; P = 0.428	26561
@NP	b = 0.049	26561
@NP	b	26561
@NP	0.049	26565
@NP	P = 0.428	26572
@NP	P	26572
@NP	0.428	26576
@NP	A and B , solid lines	26587
@NP	linear relationships	26617
@NP	lines	26649
@NP	95 % confidence intervals	26664
@NP	-LRB- C -RRB- Latencies of transcranial magnetic motor-evoked potentials	26690
@NP	-LRB- C -RRB- Latencies	26690
@NP	C	26691
@NP	transcranial magnetic motor-evoked potentials	26707
@NP	and 6 months	26769
@NP	intervention	26788
@NP	individual dog size -LRB- each symbol represents a single individual -RRB-	26818
@NP	individual dog size	26818
@NP	each symbol	26839
@NP	a single individual	26862
@NP	There	26884
@NP	no difference	26894
@NP	recovery incidence	26911
@NP	Fisher exact test P = 1.00	26931
@NP	Fisher	26931
@NP	exact test P = 1.00	26938
@NP	exact test P	26938
@NP	1.00	26953
@NP	final latencies	26962
@NP	P	26979
@NP	= 0.544 , Mann -- Whitney test	26981
@NP	= 0.544	26981
@NP	Mann	26990
@NP	Whitney test	26995
@NP	the olfactory mucosal cell and no-cell groups	27017
@NP	-LRB- D -RRB- Latencies	27064
@NP	D	27065
@NP	recorded somatosensory-evoked potentials before and 6 months after intervention	27081
@NP	recorded somatosensory-evoked potentials	27081
@NP	and 6 months after intervention	27129
@NP	and 6 months	27129
@NP	intervention	27148
@NP	individual dog size -LRB- each symbol represents a single individual -RRB-	27174
@NP	individual dog size	27174
@NP	each symbol	27195
@NP	a single individual	27218
@NP	There	27240
@NP	no difference	27250
@NP	recovery incidence	27267
@NP	P = 1.00 , Fisher exact test	27287
@NP	P = 1.00	27287
@NP	P	27287
@NP	1.00	27291
@NP	Fisher exact test	27297
@NP	final latencies	27319
@NP	P	27336
@NP	= 0.788 , Mann -- Whitney test	27338
@NP	= 0.788	27338
@NP	Mann	27347
@NP	Whitney test	27352
@NP	the olfactory mucosal cell and no-cell groups	27374
@NP	C and D	27424
@NP	lines	27433
@NP	mean and SEM	27448
@NP	-LRB- E -RRB- Bladder compliance measures	27462
@NP	-LRB- E -RRB-	27462
@NP	Bladder compliance measures	27466
@NP	and 6 months	27510
@NP	intervention	27529
@NP	There	27543
@NP	no difference	27553
@NP	compliance between the olfactory mucosal cell and no-cell groups	27570
@NP	compliance	27570
@NP	the olfactory mucosal cell and no-cell groups	27589
@NP	the trial period	27642
@NP	b	27660
@NP	= -0.077 ; P = 0.852 ; multivariable regression analysis	27662
@NP	= -0.077	27662
@NP	P = 0.852	27672
@NP	P	27672
@NP	0.852	27676
@NP	multivariable regression analysis	27683
@NP	Bars	27719
@NP	mean	27733
@NP	lines	27739
@NP	SEM	27754
@NP	Eighty-five companion dogs	27760
@NP	severe spinal cord injury of at least 3 months ' duration	27792
@NP	severe spinal cord injury	27792
@NP	at least 3 months ' duration	27821
@NP	at least 3 months '	27821
@NP	eligibility for the study	27867
@NP	eligibility	27867
@NP	the study	27883
@NP	34	27898
@NP	randomized subjects -LRB- Fig. 1 -RRB-	27917
@NP	randomized subjects	27917
@NP	Fig. 1	27938
@NP	The characteristics of the dogs and their baseline scores	27947
@NP	The characteristics	27947
@NP	the dogs and their baseline scores	27970
@NP	the dogs	27970
@NP	their baseline scores	27983
@NP	Tables 1 and 2 ; 31	28019
@NP	the 34 dogs	28041
@NP	spinal cord injury	28062
@NP	a result	28084
@NP	acute intervertebral disc extrusion	28096
@NP	the most common cause of acute contusive spinal cord injury	28132
@NP	the most common cause	28132
@NP	acute contusive spinal cord injury	28157
@NP	dogs -LRB- Fluehmann et al. , 2006 -RRB-	28195
@NP	dogs	28195
@NP	Fluehmann	28201
@NP	et al. , 2006	28211
@NP	et al.	28211
@NP	2006	28219
@NP	The breeds	28226
@NP	this study	28249
@NP	those affected by acute intervertebral disc extrusion	28275
@NP	those	28275
@NP	acute intervertebral disc extrusion	28293
@NP	All patients when first presented for this study	28330
@NP	All patients	28330
@NP	first	28348
@NP	this study	28368
@NP	no volitional motor function or pain sensation	28383
@NP	the pelvic limbs -LRB- i.e. equivalent to ASIA grade ` A ' in humans -RRB-	28433
@NP	the pelvic limbs	28433
@NP	i.e. equivalent to ASIA grade ` A ' in humans	28451
@NP	i.e.	28451
@NP	equivalent to ASIA grade ` A ' in humans	28456
@NP	ASIA grade	28470
@NP	` A	28481
@NP	humans	28488
@NP	Dogs	28497
@NP	intraspinal injections	28537
@NP	either autologous olfactory mucosal cells or cell transport medium	28563
@NP	autologous olfactory mucosal cells	28570
@NP	cell transport medium	28608
@NP	a 2:1 ratio -LRB- Fig. 2 -RRB-	28639
@NP	a 2:1 ratio	28639
@NP	Fig. 2	28652
@NP	All dogs	28661
@NP	the study	28683
@NP	n = 34 : olfactory mucosal cell = 23 , no cell group	28694
@NP	n = 34 : olfactory mucosal cell = 23	28694
@NP	n = 34	28694
@NP	n	28694
@NP	34	28698
@NP	olfactory mucosal cell = 23	28702
@NP	olfactory mucosal cell	28702
@NP	23	28727
@NP	no cell group	28731
@NP	11	28747
@NP	the final results , which therefore constitutes an intention-to-treat analysis	28768
@NP	the final results	28768
@NP	an intention-to-treat analysis	28815
@NP	Four dogs	28847
@NP	the study	28869
@NP	urinary tract infection	28880
@NP	n = 2	28905
@NP	n =	28905
@NP	2	28909
@NP	intravascular coagulation : n = 1 ; intrathoracic haemorrhage : n = 1	28935
@NP	intravascular coagulation	28935
@NP	n = 1	28962
@NP	n	28962
@NP	1	28966
@NP	intrathoracic haemorrhage	28969
@NP	n = 1	28996
@NP	n	28996
@NP	1	29000
@NP	postmortem examination in each case	29008
@NP	postmortem examination	29008
@NP	each case	29034
@NP	no evidence to link death to the intervention	29054
@NP	death	29074
@NP	the intervention	29083
@NP	Transient -LRB- < 48 h -RRB- mild side-effects	29101
@NP	Transient	29101
@NP	< 48 h	29112
@NP	<	29112
@NP	48 h	29113
@NP	mild side-effects	29119
@NP	mild spinal pain : n = 2 ; suspected ileus : n = 2	29138
@NP	mild	29138
@NP	spinal pain : n = 2 ;	29143
@NP	spinal pain	29143
@NP	n = 2	29156
@NP	n	29156
@NP	2	29160
@NP	ileus : n = 2	29173
@NP	ileus	29173
@NP	n = 2	29180
@NP	n	29180
@NP	2	29184
@NP	four dogs	29199
@NP	intraspinal transplantation	29215
@NP	there	29248
@NP	no evidence of long-term detrimental effects in any dog	29258
@NP	no evidence	29258
@NP	long-term detrimental effects in any dog	29273
@NP	long-term detrimental effects	29273
@NP	any dog	29306
@NP	Adverse effects	29315
@NP	Table 3	29349
@NP	the pre-specified primary outcome measure , fore -- hind coordination	29362
@NP	the pre-specified primary outcome measure	29362
@NP	fore -- hind coordination	29405
@NP	fore	29405
@NP	hind coordination	29410
@NP	there	29429
@NP	a change in score	29439
@NP	a change	29439
@NP	score	29451
@NP	the course	29464
@NP	the study	29478
@NP	a mean	29493
@NP	1.35 -LRB- SD = 0.71 -RRB- to 0.95 -LRB- SD = 0.74 -RRB-	29503
@NP	1.35 -LRB- SD = 0.71 -RRB-	29503
@NP	1.35	29503
@NP	SD	29509
@NP	0.71	29514
@NP	0.95 -LRB- SD = 0.74 -RRB-	29523
@NP	0.95	29523
@NP	SD	29529
@NP	0.74	29534
@NP	log units between the baseline	29540
@NP	log units	29540
@NP	the baseline	29558
@NP	6-month time point in the olfactory mucosal cell transplant recipients	29575
@NP	6-month time point	29575
@NP	the olfactory mucosal cell transplant recipients	29597
@NP	a change	29661
@NP	1.53 -LRB- SD = 0.94 -RRB- to 1.86 -LRB- SD = 0.89 -RRB- in the no-cell group	29675
@NP	1.53 -LRB- SD = 0.94 -RRB-	29675
@NP	1.53	29675
@NP	SD	29681
@NP	0.94	29686
@NP	1.86 -LRB- SD = 0.89 -RRB- in the no-cell group	29695
@NP	1.86 -LRB- SD = 0.89 -RRB-	29695
@NP	1.86	29695
@NP	SD = 0.89	29701
@NP	SD	29701
@NP	the no-cell group	29715
@NP	The effect size	29734
@NP	the distribution-based description of the minimal important clinical difference	29776
@NP	the distribution-based description	29776
@NP	the minimal important clinical difference	29814
@NP	0.955	29862
@NP	a ` large effect ' -LRB- Wyrwich and Wolinshy , 2000 -RRB-	29892
@NP	a ` large effect '	29892
@NP	Wyrwich and Wolinshy	29910
@NP	2000	29932
@NP	an appreciable clinical benefit in human patients	29979
@NP	an appreciable clinical benefit	29979
@NP	human patients	30014
@NP	The effect size	30030
@NP	more detail in Fig. 3	30064
@NP	more detail	30064
@NP	Fig. 3	30079
@NP	a video recording	30093
@NP	the online Supplementary material	30114
@NP	the motion analysis graphs and corresponding sequential video recordings	30175
@NP	The transplant effect	30249
@NP	more detail	30291
@NP	multivariable regression analysis	30309
@NP	baseline values	30360
@NP	inclusion as a covariate	30379
@NP	inclusion	30379
@NP	a covariate	30392
@NP	a highly significant effect	30422
@NP	olfactory mucosal cell transplantation	30453
@NP	hindlimb activity and fore	30495
@NP	hind coordination	30522
@NP	regression coefficient	30541
@NP	-LSB- b -RSB- = -0.455 -LSB- 95 % confidence interval -LRB- CI -RRB-	30564
@NP	= -0.455	30568
@NP	95 % confidence interval -LRB- CI -RRB-	30578
@NP	95 % confidence interval	30578
@NP	CI	30603
@NP	-0.784 to -0.126 -RSB-	30608
@NP	-0.784	30608
@NP	-0.126 -RSB-	30618
@NP	P = 0.007	30627
@NP	P	30627
@NP	0.007	30631
@NP	Fig. 4	30638
@NP	Fig.	30638
@NP	4	30643
@NP	Pre-intervention score -LRB- covariate -RRB-	30647
@NP	Pre-intervention score	30647
@NP	covariate	30671
@NP	a significant influence	30686
@NP	b = 0.684 -LRB- 95 % CI : 0.492 to 0.877 -RRB-	30711
@NP	b	30711
@NP	= 0.684 -LRB- 95 % CI : 0.492 to 0.877 -RRB-	30713
@NP	= 0.684	30713
@NP	95 % CI : 0.492 to 0.877	30722
@NP	95 % CI	30722
@NP	0.492 to 0.877	30730
@NP	P50 .001 -RSB- on fore	30747
@NP	P50 .001 -RSB-	30747
@NP	fore	30759
@NP	hind coordination outcome but time	30765
@NP	hind coordination outcome	30765
@NP	time	30795
@NP	intervention	30806
@NP	the test population	30823
@NP	a whole	30846
@NP	not -LSB- b = 0.012 -LRB- 95 % CI : -0.021 to 0.046 -RRB-	30859
@NP	not -LSB- b	30859
@NP	0.012	30868
@NP	95 % CI : -0.021 to 0.046	30875
@NP	95 % CI	30875
@NP	-0.021 to 0.046	30883
@NP	P = 0.474	30901
@NP	P	30901
@NP	0.474	30905
@NP	Dogs in the olfactory mucosal cell transplantation group	30913
@NP	Dogs	30913
@NP	the olfactory mucosal cell transplantation group	30921
@NP	a cell preparation	30989
@NP	6.24 -LSB- ± standard error -LRB- SE -RRB- = 0.39	31019
@NP	6.24 -LSB- ± standard error -LRB- SE -RRB-	31019
@NP	6.24 -LSB- ± standard error	31019
@NP	SE	31042
@NP	0.39	31048
@NP	106 cells	31056
@NP	total , enriched in p75 + cells to a mean purity	31069
@NP	p75 + cells to a mean	31088
@NP	p75 + cells	31088
@NP	a mean	31103
@NP	49.4 % -LRB- ± SE = 6.8 -RRB-	31120
@NP	49.4 %	31120
@NP	± SE	31127
@NP	6.8	31133
@NP	the cell preparation	31150
@NP	3.20 -LRB- ± SE = 0.49 -RRB-	31187
@NP	3.20	31187
@NP	± SE	31193
@NP	0.49	31199
@NP	10 ^ 6 p75	31207
@NP	10 ^	31207
@NP	6 p75	31210
@NP	cells -LRB- assumed to be olfactory ensheathing cells -RRB- , 2.82	31218
@NP	cells -LRB- assumed to be olfactory ensheathing cells -RRB-	31218
@NP	cells	31218
@NP	olfactory ensheathing cells	31239
@NP	2.82	31269
@NP	± SE	31275
@NP	0.49	31281
@NP	10	31289
@NP	^ 6 fibronectinexpressing cells	31291
@NP	likely to be fibroblasts derived from the sub-mucosa	31323
@NP	fibroblasts derived from the sub-mucosa	31336
@NP	fibroblasts	31336
@NP	the sub-mucosa	31361
@NP	0.21 -LRB- ± SE = 0.06 -RRB- x 106 unidentified cells	31382
@NP	0.21 -LRB- ± SE = 0.06 -RRB-	31382
@NP	0.21	31382
@NP	± SE	31388
@NP	0.06	31394
@NP	106 unidentified cells	31402
@NP	Supplementary Fig. 3	31426
@NP	cell transplant recipients	31452
@NP	there	31480
@NP	no significant relationship between forelimb	31490
@NP	no significant relationship	31490
@NP	forelimb	31526
@NP	hindlimb coordination	31535
@NP	the proportion	31561
@NP	p75 + cells	31579
@NP	the transplant	31608
@NP	each dog	31623
@NP	transplanted	31650
@NP	b = -0.002 -LRB- 95 % CI : -0.009 to 0.005 -RRB-	31664
@NP	b	31664
@NP	-0.002	31668
@NP	95 % CI : -0.009 to 0.005	31676
@NP	95 % CI	31676
@NP	-0.009 to 0.005	31684
@NP	P = 0.52 -RSB-	31702
@NP	P	31702
@NP	0.52 -RSB-	31706
@NP	We	31713
@NP	a series	31730
@NP	secondary outcome measures	31742
@NP	the effect	31789
@NP	the intervention on sensory and motor spinal cord long tract function	31803
@NP	the intervention on sensory	31803
@NP	the intervention	31803
@NP	sensory	31823
@NP	motor spinal cord long tract function	31835
@NP	motor spinal cord	31835
@NP	long tract function	31853
@NP	Somatosensory-evoked potentials	32357
@NP	the scalp in 12 of the 34 dogs	32412
@NP	the scalp	32412
@NP	12 of the 34 dogs	32425
@NP	12	32425
@NP	the 34 dogs	32431
@NP	trial entry	32446
@NP	the latency of this response	32463
@NP	the latency	32463
@NP	this response	32478
@NP	mean latency reduction = 0.85 ms	32513
@NP	mean latency reduction = 0.85	32513
@NP	mean latency reduction	32513
@NP	ms	32543
@NP	the study period	32554
@NP	An additional two dogs regained	32572
@NP	An additional two dogs	32572
@NP	somatosensory	32604
@NP	potentials	32626
@NP	the end of the trial , of which one had received olfactory mucosal cells	32640
@NP	the end	32640
@NP	the trial , of which one had received olfactory mucosal cells	32651
@NP	the trial	32651
@NP	one	32671
@NP	olfactory mucosal cells	32688
@NP	Transcranial magnetic motorevoked potentials	32713
@NP	the tibialis cranialis muscle	32779
@NP	intervention in 13 dogs	32816
@NP	intervention	32816
@NP	13 dogs	32832
@NP	An additional three dogs	32841
@NP	this response	32875
@NP	the 6-month trial period , two of which had received olfactory mucosal cells	32896
@NP	the 6-month trial period	32896
@NP	olfactory mucosal cells	32948
@NP	There	32973
@NP	no difference	32983
@NP	incidence	33000
@NP	recovery of somatosensory-evoked potentials	33013
@NP	recovery	33013
@NP	somatosensory-evoked potentials	33025
@NP	transcranial magnetic motor-evoked potentials	33060
@NP	groups -LRB- Fisher exact test , P = 1.00 for each -RRB-	33114
@NP	groups	33114
@NP	Fisher exact test , P = 1.00 for each	33122
@NP	Fisher exact test	33122
@NP	P = 1.00 for each	33141
@NP	P = 1.00	33141
@NP	P	33141
@NP	1.00	33145
@NP	each	33154
@NP	Urinary bladder compliance	33161
@NP	a measure	33189
@NP	CNS modulation of bladder activity -LRB- Biering-Sørensen et al. , 2008 -RRB-	33202
@NP	CNS modulation	33202
@NP	bladder activity -LRB- Biering-Sørensen et al. , 2008 -RRB-	33220
@NP	bladder activity	33220
@NP	Biering-Sørensen	33238
@NP	et al. , 2008	33255
@NP	et al.	33255
@NP	2008	33263
@NP	31 dogs throughout the trial	33288
@NP	31 dogs	33288
@NP	the trial	33307
@NP	olfactory mucosal cell	33344
@NP	no-cell groups -LSB- b = -0.077 -LRB- 95 % CI : -0.891 to 0.736 -RRB-	33371
@NP	no-cell groups	33371
@NP	b = -0.077 -LRB- 95 % CI : -0.891 to 0.736 -RRB-	33387
@NP	b = -0.077	33387
@NP	b	33387
@NP	-0.077	33391
@NP	95 % CI : -0.891 to 0.736	33399
@NP	95 % CI	33399
@NP	-0.891 to 0.736	33407
@NP	P = 0.852	33425
@NP	P	33425
@NP	0.852	33429
@NP	analysis by multivariable regression	33436
@NP	analysis	33436
@NP	multivariable regression	33448
@NP	Discussion	33500
@NP	The results of this study	33511
@NP	The results	33511
@NP	this study	33526
@NP	injection of olfactory mucosa-derived cells in a blinded	33561
@NP	injection	33561
@NP	olfactory mucosa-derived cells in a blinded	33574
@NP	olfactory mucosa-derived cells	33574
@NP	a blinded	33608
@NP	trial	33629
@NP	improvements in locomotor outcome	33654
@NP	improvements	33654
@NP	locomotor outcome	33670
@NP	chronic clinical spinal cord injury	33691
@NP	This result	33728
@NP	a substantial advance	33743
@NP	previously available laboratory data	33768
@NP	intraspinal olfactory cell transplantation	33815
@NP	it	33866
@NP	the beneficial effects	33886
@NP	clinical cases	33958
@NP	the ` noise '	33983
@NP	other uncontrolled variables	33998
@NP	precise character of the injury	34036
@NP	precise character	34036
@NP	the injury	34057
@NP	an effect	34075
@NP	the effects	34124
@NP	cases	34166
@NP	chronic spinal cord injury	34177
@NP	a plateau of recovery	34232
@NP	a plateau	34232
@NP	recovery	34245
@NP	some of the dogs	34256
@NP	some	34256
@NP	the dogs	34264
@NP	412 months	34297
@NP	sufficient magnitude	34322
@NP	locomotor patterns	34353
@NP	a clinically useful effect -LRB- Supplementary Fig. 2 -RRB-	34377
@NP	a clinically useful effect	34377
@NP	Supplementary Fig. 2	34405
@NP	Supplementary Fig.	34405
@NP	2	34424
@NP	It	34428
@NP	experimental animals	34451
@NP	interventions in chronic spinal cord injury	34477
@NP	interventions	34477
@NP	chronic spinal cord injury	34494
@NP	a detectable benefit	34529
@NP	the numerous obstacles to regeneration	34561
@NP	the numerous obstacles	34561
@NP	regeneration	34587
@NP	functional recovery at this stage -LRB- Kadoya et al. , 2009 -RRB-	34604
@NP	functional recovery	34604
@NP	this stage -LRB- Kadoya et al. , 2009 -RRB-	34627
@NP	this stage	34627
@NP	Kadoya	34639
@NP	et al. , 2009	34646
@NP	et al.	34646
@NP	2009	34654
@NP	these data	34673
@NP	improvement in spinal cord connectivity	34697
@NP	improvement	34697
@NP	spinal cord connectivity	34712
@NP	human patients	34772
@NP	they	34790
@NP	a similar intervention , such as those enrolled in the recently reported Phase	34811
@NP	a similar intervention	34811
@NP	those enrolled in the recently reported Phase	34843
@NP	those	34843
@NP	the recently reported Phase	34861
@NP	I	34889
@NP	human trials	34891
@NP	Lima	34905
@NP	et al. , 2008 ; 2010 ; Mackay-Sim et al. , 2008 ; Chhandra et al. , 2009	34910
@NP	et al.	34910
@NP	2008 ; 2010 ; Mackay-Sim et al. , 2008 ; Chhandra et al.	34918
@NP	2008 ; 2010	34918
@NP	2008	34918
@NP	2010	34924
@NP	Mackay-Sim et al. , 2008	34930
@NP	Mackay-Sim	34930
@NP	et al. , 2008	34941
@NP	et al.	34941
@NP	2008	34949
@NP	Chhandra et al.	34955
@NP	Chhandra	34955
@NP	et al.	34964
@NP	2009	34972
@NP	it	34988
@NP	improvement on our primary outcome measure	35022
@NP	improvement	35022
@NP	our primary outcome measure	35037
@NP	a composite	35068
@NP	increase in spinal stepping activity	35088
@NP	increase	35088
@NP	spinal stepping activity	35100
@NP	a non-stepping dog	35129
@NP	forelimbs and hindlimbs	35166
@NP	increase in hindlimb step coordination with the forelimbs	35195
@NP	increase	35195
@NP	hindlimb step coordination with the forelimbs	35207
@NP	hindlimb step coordination	35207
@NP	the forelimbs	35239
@NP	restoration of brain control	35284
@NP	restoration	35284
@NP	brain control	35299
@NP	hindlimb motion	35318
@NP	Our secondary outcome measures	35335
@NP	insight	35391
@NP	mechanisms	35404
@NP	olfactory mucosal cell transplantation	35424
@NP	its effects	35480
@NP	experimental studies on focal lesions in rodents	35496
@NP	experimental studies	35496
@NP	focal lesions in rodents	35520
@NP	focal lesions	35520
@NP	rodents	35537
@NP	there	35546
@NP	strong evidence	35555
@NP	olfactory ensheathing cells	35576
@NP	regeneration	35616
@NP	long tract -LRB- e.g. pyramidal tract -RRB- axons -LRB- Li et al. , 1998 -RRB-	35632
@NP	long tract -LRB- e.g. pyramidal tract -RRB- axons	35632
@NP	e.g. pyramidal tract	35644
@NP	e.g.	35644
@NP	pyramidal tract	35649
@NP	Li	35673
@NP	et al. , 1998	35676
@NP	et al.	35676
@NP	1998	35684
@NP	olfactory	35695
@NP	cell-mediated functional improvement in complete transection models	35717
@NP	cell-mediated functional improvement	35717
@NP	complete transection models	35757
@NP	serotonergic fibre regeneration -LRB- Ramon-Cueto et al. , 2000 -RRB-	35817
@NP	serotonergic fibre regeneration	35817
@NP	Ramon-Cueto	35850
@NP	et al. , 2000	35862
@NP	et al.	35862
@NP	2000	35870
@NP	The improved forelimb -- hindlimb coordination we observed	35877
@NP	The	35877
@NP	hindlimb coordination we observed	35899
@NP	hindlimb coordination	35899
@NP	we	35921
@NP	enhanced communication across the damaged region of spinal cord	35941
@NP	enhanced communication	35941
@NP	the damaged region of spinal cord	35971
@NP	the damaged region	35971
@NP	spinal cord	35993
@NP	long-range axon regeneration	36042
@NP	our data	36081
@NP	this	36112
@NP	these dogs -- most notably the lack of improvement	36142
@NP	these dogs	36142
@NP	the lack of improvement	36168
@NP	the lack	36168
@NP	improvement	36180
@NP	any	36195
@NP	our measures	36202
@NP	long tract function	36218
@NP	i.e.	36239
@NP	lateral stability	36244
@NP	somatosensory-evoked potential	36263
@NP	transcranial magnetic motorevoked potential	36295
@NP	urodynamics	36343
@NP	the concomitant improvement in fore -- hind coordination	36364
@NP	the concomitant improvement in fore	36364
@NP	the concomitant improvement	36364
@NP	fore	36395
@NP	hind coordination	36400
@NP	plastic changes in propriospinal connections	36428
@NP	plastic changes	36428
@NP	propriospinal connections	36447
@NP	an explanation for improvement in fore	36481
@NP	an explanation	36481
@NP	improvement in fore	36500
@NP	improvement	36500
@NP	fore	36515
@NP	hind coordination that is more consistent with the data	36520
@NP	hind coordination	36520
@NP	the data	36567
@NP	Such an effect	36577
@NP	many processes including	36610
@NP	many processes	36610
@NP	, local axon sprouting	36654
@NP	, local axon	36654
@NP	Many other	36678
@NP	previously documented properties of olfactory ensheathing cells	36689
@NP	previously documented properties	36689
@NP	olfactory ensheathing cells	36725
@NP	modulation	36780
@NP	immune responses -LRB- Arnold and Hagg , 2011 ; Chuah et al. , 2011 -RRB-	36794
@NP	immune responses	36794
@NP	Arnold and Hagg , 2011 ; Chuah et al. , 2011	36812
@NP	Arnold and Hagg	36812
@NP	2011 ; Chuah et al.	36829
@NP	2011	36829
@NP	Chuah et al.	36835
@NP	Chuah	36835
@NP	et al.	36841
@NP	2011	36849
@NP	provision	36856
@NP	neurotrophic factors -LRB- Chiu et al. , 2009 -RRB- , remyelination of	36869
@NP	neurotrophic factors -LRB- Chiu et al. , 2009 -RRB-	36869
@NP	neurotrophic factors	36869
@NP	Chiu	36891
@NP	et al. , 2009	36896
@NP	et al.	36896
@NP	2009	36904
@NP	remyelination of	36911
@NP	remyelination	36911
@NP	axons	36941
@NP	Franklin	36948
@NP	et al. , 1996 ; Sasaki et al. , 2011	36957
@NP	et al.	36957
@NP	1996 ; Sasaki et al.	36965
@NP	1996	36965
@NP	Sasaki et al.	36971
@NP	Sasaki	36971
@NP	et al.	36978
@NP	2011	36986
@NP	modulation of glia and neuronal function -LRB- Chuah et al. , 2011 -RRB-	36995
@NP	modulation	36995
@NP	glia and neuronal function -LRB- Chuah et al. , 2011 -RRB-	37009
@NP	glia and neuronal function	37009
@NP	Chuah	37037
@NP	et al. , 2011	37043
@NP	et al.	37043
@NP	2011	37051
@NP	It	37058
@NP	the effects of the olfactory mucosal cell transplant	37083
@NP	the effects	37083
@NP	the olfactory mucosal cell transplant	37098
@NP	effects	37164
@NP	the olfactory ensheathing cell component of the transplanted population	37184
@NP	the olfactory ensheathing cell component	37184
@NP	the transplanted population	37228
@NP	Our data	37257
@NP	a clear and strong overall effect of olfactory mucosal cell transplants	37271
@NP	a clear and strong overall effect	37271
@NP	olfactory mucosal cell transplants	37308
@NP	extent of recovery	37348
@NP	extent	37348
@NP	recovery	37358
@NP	the total proportion of p75	37396
@NP	the total proportion	37396
@NP	p75	37420
@NP	olfactory ensheathing cells contained within the transplant population	37426
@NP	olfactory ensheathing cells	37426
@NP	the transplant population	37471
@NP	a similar observation	37513
@NP	transplantation of olfactory mucosa-derived cells	37560
@NP	transplantation	37560
@NP	olfactory mucosa-derived cells	37579
@NP	rat models of spinal cord injury -LRB- Yamamoto et al. , 2009 -RRB-	37613
@NP	rat models	37613
@NP	spinal cord injury -LRB- Yamamoto et al. , 2009 -RRB-	37627
@NP	spinal cord injury	37627
@NP	Yamamoto	37647
@NP	et al. , 2009	37656
@NP	et al.	37656
@NP	2009	37664
@NP	This finding	37671
@NP	the possibility	37701
@NP	the effect	37722
@NP	a threshold number of olfactory ensheathing cells	37754
@NP	a threshold number	37754
@NP	olfactory ensheathing cells	37776
@NP	the population , which might be quite low	37811
@NP	the population	37811
@NP	it	37867
@NP	the precise type of cells in the transplant	37889
@NP	the precise type	37889
@NP	cells in the transplant	37909
@NP	cells	37909
@NP	the transplant	37918
@NP	the success of mucosal-derived transplants	37952
@NP	the success	37952
@NP	mucosal-derived transplants	37967
@NP	It	37996
@NP	their effects	38031
@NP	a result	38054
@NP	local axon sprouting -LRB- Yamamoto et al. , 2009 -RRB-	38066
@NP	local axon sprouting	38066
@NP	local axon	38066
@NP	Yamamoto	38088
@NP	et al. , 2009	38097
@NP	et al.	38097
@NP	2009	38105
@NP	the long-range axon regeneration	38123
@NP	formation	38172
@NP	bridges ' across the lesion site	38186
@NP	bridges '	38186
@NP	the lesion site	38202
@NP	other types of olfactory cell transplants -LRB- Raisman and Li , 2007 -RRB-	38248
@NP	other types	38248
@NP	olfactory cell transplants -LRB- Raisman and Li , 2007 -RRB-	38263
@NP	olfactory cell transplants	38263
@NP	Raisman and Li , 2007	38291
@NP	Raisman	38291
@NP	Li , 2007	38303
@NP	Li	38303
@NP	2007	38307
@NP	This explanation	38314
@NP	the observation	38353
@NP	the effect in our study	38374
@NP	the effect	38374
@NP	our study	38388
@NP	the intraspinal connectivity -LRB- i.e. acting at a local level -RRB-	38422
@NP	the intraspinal connectivity	38422
@NP	i.e. acting at a local level	38452
@NP	i.e.	38452
@NP	a local level	38467
@NP	communication between spinal locomotor centres and the brain	38494
@NP	communication	38494
@NP	spinal locomotor centres and the brain	38516
@NP	spinal locomotor centres	38516
@NP	the brain	38545
@NP	the precise relationship between transplanted olfactory mucosal cell	38579
@NP	the precise relationship	38579
@NP	transplanted olfactory mucosal cell	38612
@NP	functional outcome	38652
@NP	it	38672
@NP	the survival of transplanted cells within host tissue	38707
@NP	the survival	38707
@NP	transplanted cells within host tissue	38723
@NP	transplanted cells	38723
@NP	host tissue	38749
@NP	A percutaneous cell transplantation technique	38762
@NP	this study	38820
@NP	blinded comparison	38853
@NP	intraspinal injections	38880
@NP	cells	38932
@NP	Percutaneous delivery of cells	38939
@NP	Percutaneous delivery	38939
@NP	cells	38964
@NP	the need for a sham surgical procedure in the control animals	38977
@NP	the need	38977
@NP	a sham surgical procedure in the control animals	38990
@NP	a sham surgical procedure	38990
@NP	the control animals	39019
@NP	blinding purposes	39051
@NP	similar avoidance	39075
@NP	the ethical problems	39096
@NP	sham	39133
@NP	neurosurgical procedures -LRB- Galpern et al. , 2012 -RRB-	39138
@NP	neurosurgical procedures	39138
@NP	Galpern	39164
@NP	et al. , 2012	39172
@NP	et al.	39172
@NP	2012	39180
@NP	value during translation	39203
@NP	value	39203
@NP	translation	39216
@NP	human patients	39233
@NP	Our previous intraspinal cell transplantation technique	39249
@NP	Jeffery	39306
@NP	et al. , 2005	39314
@NP	et al.	39314
@NP	2005	39322
@NP	surgical exposure of the spinal cord	39332
@NP	surgical exposure	39332
@NP	the spinal cord	39353
@NP	accurate needle placement	39377
@NP	the spinal cord parenchyma	39408
@NP	cells	39486
@NP	their target site	39495
@NP	cerebrospinal fluid	39524
@NP	spinal puncture	39551
@NP	unequivocal evidence of needle bevel position within an intradural location	39576
@NP	unequivocal evidence	39576
@NP	needle bevel position within an intradural location	39600
@NP	needle bevel position	39600
@NP	an intradural location	39629
@NP	needle stability during injection	39657
@NP	needle stability	39657
@NP	injection	39681
@NP	the surrounding soft tissue	39715
@NP	transplant leakage	39760
@NP	It	39780
@NP	no detrimental effects on the recipients	39832
@NP	no detrimental effects	39832
@NP	the recipients	39858
@NP	human medicine	39920
@NP	human patients with spinal cord injury	39939
@NP	human patients	39939
@NP	spinal cord injury	39959
@NP	introduction of a larger number of needles	39979
@NP	introduction	39979
@NP	a larger number of needles	39995
@NP	a larger number	39995
@NP	needles	40014
@NP	delivery of cells	40048
@NP	delivery	40048
@NP	cells	40060
@NP	the whole length of lesions	40069
@NP	the whole length	40069
@NP	lesions	40089
@NP	severe fracture luxations	40112
@NP	much greater relative size	40155
@NP	the lesions treated in the current study	40187
@NP	the lesions	40187
@NP	the current study	40210
@NP	A major reason for carrying out this study	40229
@NP	A major reason	40229
@NP	this study	40261
@NP	intraspinal transplantation of olfactory mucosal cell	40297
@NP	intraspinal transplantation	40297
@NP	olfactory mucosal cell	40328
@NP	an appropriate subject	40360
@NP	expeditious clinical efficacy trials in human patients with spinal cord injury	40387
@NP	expeditious clinical efficacy trials	40387
@NP	human patients with spinal cord injury	40427
@NP	human patients	40427
@NP	spinal cord injury	40447
@NP	Several groups throughout the world	40467
@NP	Several groups	40467
@NP	the world	40493
@NP	Phase	40528
@NP	I trials	40534
@NP	olfactory ensheathing cell transplantation	40546
@NP	spinal cord injury	40593
@NP	humans	40615
@NP	Lima	40623
@NP	et al. , 2006 , 2010 ; Mackay-Sim et al. , 2008 ; Chhabra et al. , 2009	40628
@NP	et al.	40628
@NP	2006 , 2010 ; Mackay-Sim et al. , 2008 ; Chhabra et al.	40636
@NP	2006 , 2010	40636
@NP	2006	40636
@NP	2010	40642
@NP	Mackay-Sim et al. , 2008	40648
@NP	Mackay-Sim	40648
@NP	et al. , 2008	40659
@NP	et al.	40659
@NP	2008	40667
@NP	Chhabra et al.	40673
@NP	Chhabra	40673
@NP	et al.	40681
@NP	2009	40689
@NP	the safety of this approach	40710
@NP	the safety	40710
@NP	this approach	40724
@NP	Efficacy testing	40739
@NP	much greater resources	40769
@NP	very careful consideration	40812
@NP	this study	40843
@NP	we	40864
@NP	olfactory mucosal cell transplantation	40884
@NP	communication	40932
@NP	the lesion	40953
@NP	recovery of ` automatic ' coordination between forelimbs and hindlimbs	40974
@NP	recovery	40974
@NP	` automatic ' coordination between forelimbs and hindlimbs	40986
@NP	` automatic ' coordination	40986
@NP	forelimbs and hindlimbs	41019
@NP	there	41044
@NP	few data to support improvement of spinal long tract function	41054
@NP	improvement of spinal long tract function	41074
@NP	improvement	41074
@NP	spinal long tract function	41089
@NP	Human spinal cord injury patients most	41117
@NP	Human spinal cord injury patients	41117
@NP	most	41151
@NP	recovery	41162
@NP	arm , bladder and sexual function -LRB- Anderson , 2004 -RRB-	41174
@NP	arm , bladder and sexual function	41174
@NP	Anderson	41208
@NP	2004	41218
@NP	spinal long tract function	41255
@NP	the brain	41297
@NP	lower motor	41327
@NP	neuron activity	41339
@NP	it	41376
@NP	olfactory mucosal cells	41416
@NP	human spinal cord injury patients	41445
@NP	clinically detectable effects	41504
@NP	it	41535
@NP	patients	41557
@NP	useful benefit	41583
@NP	their everyday lives	41601
@NP	Barnett and Riddell , 2007	41631
@NP	Barnett and Riddell	41631
@NP	2007	41652
@NP	that reason	41663
@NP	the main implication of our study	41676
@NP	the main implication	41676
@NP	our study	41700
@NP	it	41718
@NP	encouragement	41738
@NP	that olfactory mucosal cell transplants	41764
@NP	a sole treatment	41807
@NP	significant clinical benefit	41838
@NP	human spinal cord injury patients	41870
@NP	the effects we show here	41919
@NP	the effects	41919
@NP	we	41931
@NP	some worthwhile benefit	41956
@NP	the olfactory mucosal cell transplant	41983
@NP	part of a multimodal intervention	42032
@NP	part	42032
@NP	a multimodal intervention	42040
@NP	a future therapeutic strategy -LRB- Thuret et al. , 2006 -RRB-	42104
@NP	a future therapeutic strategy	42104
@NP	Thuret	42135
@NP	et al. , 2006	42142
@NP	et al.	42142
@NP	2006	42150
@NP	some previous human studies	42160
@NP	olfactory mucosal cell transplantation	42189
@NP	rehabilitation therapies -LRB- Chhabra et al. , 2009 ; Lima et al. , 2010 -RRB-	42252
@NP	rehabilitation therapies	42252
@NP	Chhabra	42278
@NP	et al. , 2009 ; Lima et al. , 2010	42286
@NP	et al.	42286
@NP	2009 ; Lima et al.	42294
@NP	2009	42294
@NP	Lima et al.	42300
@NP	Lima	42300
@NP	et al.	42305
@NP	2010	42313
@NP	themselves	42329
@NP	a beneficial effect on outcome	42349
@NP	a beneficial effect	42349
@NP	outcome	42372
@NP	interpretation of the origin of the observed effects	42402
@NP	interpretation	42402
@NP	the origin of the observed effects	42420
@NP	the origin	42420
@NP	the observed effects	42434
@NP	our current study	42459
@NP	the extent of physical exercise	42487
@NP	the extent	42487
@NP	physical exercise	42501
@NP	individuals	42534
@NP	there	42547
@NP	no systematic difference between groups of transplanted and control dogs	42557
@NP	no systematic difference	42557
@NP	groups of transplanted and control dogs	42590
@NP	groups	42590
@NP	transplanted and control dogs	42600
@NP	transplanted	42600
@NP	control dogs	42617
@NP	it	42635
@NP	an alternative explanation for our findings	42652
@NP	an alternative explanation	42652
@NP	our findings	42683
@NP	The information gained in this project	42697
@NP	The information	42697
@NP	this project	42723
@NP	the contributions	42748
@NP	study of spinal cord injury	42786
@NP	study	42786
@NP	spinal cord injury	42795
@NP	pet dogs	42817
@NP	a bridge between the laboratory and human clinic	42840
@NP	a bridge	42840
@NP	the laboratory and human clinic	42857
@NP	the laboratory	42857
@NP	human clinic	42876
@NP	promising therapies identified through previous research in rodents	42896
@NP	promising therapies	42896
@NP	previous research in rodents	42935
@NP	previous research	42935
@NP	rodents	42956
@NP	efficacy in this ` clinical model '	42984
@NP	efficacy	42984
@NP	this ` clinical model '	42996
@NP	human trials	43038
@NP	This translational aspect	43052
@NP	the provision	43096
@NP	relatively heterogeneous patient groups -LRB- similar to human patients -RRB-	43113
@NP	relatively heterogeneous patient groups	43113
@NP	human patients	43165
@NP	assessment	43204
@NP	electrophysiological testing	43221
@NP	quantitative functional neurological data	43272
@NP	The conclusion drawn from this approach	43315
@NP	The conclusion	43315
@NP	this approach	43341
@NP	olfactory mucosa-derived cell transplants	43363
@NP	substantial change	43417
@NP	function in a clinical spinal cord injury model	43439
@NP	function	43439
@NP	a clinical spinal cord injury model	43451
@NP	the effects	43497
@NP	local intraspinal circuitry	43529
@NP	long tract function	43572
@NP	us	43605
@NP	this intervention	43625
@NP	appreciable benefits in the treatment of human spinal cord injury	43669
@NP	appreciable benefits	43669
@NP	the treatment of human spinal cord injury	43693
@NP	the treatment	43693
@NP	human spinal cord injury	43710
@NP	a useful component of a multi-faceted approach	43762
@NP	a useful component	43762
@NP	a multi-faceted approach	43784
@VP	to ameliorate the effects of experimental spinal cord injury	777
@VP	ameliorate the effects of experimental spinal cord injury	780
@VP	could provide sufficient benefit to be of value to clinical cases	838
@VP	provide sufficient benefit to be of value to clinical cases	844
@VP	to be of value to clinical cases	871
@VP	be of value to clinical cases	874
@VP	improves locomotor outcome after spinal cord injury in ` proof of principle '	960
@VP	suggesting the possibility of efficacy in human patients	1060
@VP	can not accurately model the inherent heterogeneity of clinical patient cohorts	1164
@VP	model the inherent heterogeneity of clinical patient cohorts	1182
@VP	containing a mean of ≈ 50 % olfactory ensheathing cells	1447
@VP	involved in transition from laboratory to clinic	1610
@VP	receiving cell transport medium alone	2131
@VP	find no evidence for concomitant improvement in long tract function	2483
@VP	/	2820
@VP	are designed to develop new therapies	3374
@VP	designed to develop new therapies	3378
@VP	to develop new therapies	3387
@VP	develop new therapies	3390
@VP	will tend to obscure detection of the effect of interest	3930
@VP	tend to obscure detection of the effect of interest	3935
@VP	may not be of sufficient magnitude to be clinically meaningful to patients	4070
@VP	be of sufficient magnitude to be clinically meaningful to patients	4078
@VP	to be clinically meaningful to patients	4105
@VP	be clinically meaningful to patients	4108
@VP	to obstruct effective translation	4177
@VP	obstruct effective translation	4180
@VP	can be difficult to discern using conventional laboratory models	4340
@VP	be difficult to discern using conventional laboratory models	4344
@VP	to discern using conventional laboratory models	4357
@VP	discern using conventional laboratory models	4360
@VP	using conventional laboratory models	4368
@VP	can be tested	4694
@VP	be tested	4698
@VP	tested	4701
@VP	To conduct a clinical trial of a putative therapy for spinal cord injury in dogs	4868
@VP	conduct a clinical trial of a putative therapy for spinal cord injury in dogs	4871
@VP	derived from olfactory mucosa cell cultures	5428
@VP	containing ≈ 50 % p75 + olfactory ensheathing cells	5473
@VP	involved in translating a putative therapy from laboratory to clinic	5615
@VP	translating a putative therapy from laboratory to clinic	5627
@VP	had previously sustained severe acute spinal cord injury	5841
@VP	obtained from detailed objective analysis of locomotor coordination	6267
@VP	might exert an effect	6482
@VP	exert an effect	6488
@VP	recruited for this study between October 2008	6622
@VP	March 2011 through professional contacts	6672
@VP	presentations at veterinary conferences and notices on websites	6714
@VP	specified that dogs should weigh < 20 kg	6797
@VP	should weigh < 20 kg	6817
@VP	weigh < 20 kg	6824
@VP	has seven lumbar segments and terminates at ≈ L5 vertebra	6938
@VP	has seven lumbar segments	6938
@VP	terminates at ≈ L5 vertebra	6968
@VP	applied to the hindquarters	7107
@VP	is equivalent to ≈ 12 months after injury in human patients	7414
@VP	to ≈ 12 months after injury in human patients	7428
@VP	≈ 12 months after injury in human patients	7431
@VP	stepping during treadmill	7564
@VP	would preclude accurate locomotor assessment	7867
@VP	preclude accurate locomotor assessment	7873
@VP	were given with therapeutic intent	8062
@VP	given with therapeutic intent	8067
@VP	had previous data suggesting an immediate effect after intraspinal injections	8101
@VP	suggesting an immediate effect after intraspinal injections	8119
@VP	was carried out	8390
@VP	carried out	8394
@VP	would have a beneficial effect ; our previous study	8585
@VP	have a beneficial effect ; our previous study	8591
@VP	was safe in dogs -LRB- Jeffery et al. , 2005 -RRB-	8711
@VP	is illustrated in Fig. 1	9080
@VP	illustrated in Fig. 1	9083
@VP	met all of the inclusion criteria and none of the exclusion criteria	9131
@VP	were admitted to the study	9200
@VP	admitted to the study	9205
@VP	was anaesthetized	9307
@VP	anaesthetized	9311
@VP	were placed into the lesion site -LRB- see later in the text -RRB-	9341
@VP	placed into the lesion site -LRB- see later in the text -RRB-	9346
@VP	see later in the text	9375
@VP	achieved through opening a sealed opaque envelope	9553
@VP	opening a sealed opaque envelope	9570
@VP	containing the word ` cells ' or ` medium '	9609
@VP	were used , owing to time and financial constraints	9712
@VP	used , owing to time and financial constraints	9717
@VP	owing to time and financial constraints	9723
@VP	contained 12 envelopes containing ` cells '	9779
@VP	containing ` cells '	9802
@VP	containing ` medium '	9829
@VP	sealing	9856
@VP	were shuffled by hand	9879
@VP	shuffled by hand	9884
@VP	administered the different treatments	9999
@VP	might have effect on only a proportion of transplanted animals	10107
@VP	have effect on only a proportion of transplanted animals	10113
@VP	recording the outcome measures	10310
@VP	were blinded to intervention allocation until completion of data analysis	10341
@VP	blinded to intervention allocation until completion of data analysis	10346
@VP	was examined by a specialist veterinary neurologist -LRB- N.D.J. or N.G. -RRB-	10459
@VP	examined by a specialist veterinary neurologist -LRB- N.D.J. or N.G. -RRB-	10463
@VP	then underwent standard T1 - and T2-weighted magnetic resonance	10532
@VP	see later in the text	10689
@VP	given at time = 0	10870
@VP	carried out as previously described -LRB- Hamilton et al. , 2007 , 2008 -RRB-	10922
@VP	described	10948
@VP	were made of limb motion using gait analysis equipment -LRB- Qualisys -RRB-	11131
@VP	made of limb motion using gait analysis equipment -LRB- Qualisys -RRB-	11136
@VP	using gait analysis equipment -LRB- Qualisys -RRB-	11156
@VP	here termed ` fore -- hind coordination '	11378
@VP	using the coefficient of variation of the distance between hindlimb paws	11556
@VP	here termed ` lateral stability '	11630
@VP	used to determine coordination between hindlimb paws and body position	11666
@VP	to determine coordination between hindlimb paws and body position	11671
@VP	determine coordination between hindlimb paws and body position	11674
@VP	stepping rhythm of the hindlimbs	11837
@VP	is almost constant despite different treadmill speeds	11877
@VP	also correspond to the voluntary stepping rhythm of the forelimbs	11936
@VP	stepping rhythm of the forelimbs	11969
@VP	recorded locomotion at two speeds	12005
@VP	thereby eliminating the potential for ` entrainment ' to produce inaccurate data	12156
@VP	to produce inaccurate data	12208
@VP	produce inaccurate data	12211
@VP	stepping	12398
@VP	determined and entered into statistical analysis	12463
@VP	using signal averaging -LRB- 256 sweeps -RRB-	13037
@VP	positioned over the motor cortex	13350
@VP	discharged , while recording from the cranial tibial muscle	13387
@VP	recording from the cranial tibial muscle	13405
@VP	using conventional urodynamic equipment -LRB- Life-Tech , Urolab Primus 6 -RRB-	13559
@VP	were completed	13930
@VP	completed	13935
@VP	underwent general anaesthesia	13955
@VP	kept on ice	14316
@VP	transported from the operating room	14332
@VP	to be processed	14386
@VP	be processed	14389
@VP	processed	14392
@VP	chopped with a scalpel blade for 1 min	14601
@VP	containing 0.25 mg of 112	14720
@VP	containing 0.5 mg of bovine pancreas DNase	14819
@VP	was added	14861
@VP	added	14865
@VP	triturated for 1 min through glass pipettes	14890
@VP	filtered -LRB- 40µm filter -RRB-	14935
@VP	containing 10 %	15008
@VP	centrifuged -LRB- 1000 rpm , 5 min -RRB-	15047
@VP	seeded -LRB- 10 000 to 50 000 viable cells/ml -RRB- onto poly-L-lysine	15288
@VP	were maintained at 37 °C in 5 % carbon dioxide	15380
@VP	maintained at 37 °C in 5 % carbon dioxide	15385
@VP	were undisturbed for 5 -- 7 days to allow cell adhesion	15458
@VP	to allow cell adhesion	15488
@VP	allow cell adhesion	15491
@VP	was renewed every 3 days	15554
@VP	renewed every 3 days	15558
@VP	was used to detach the cells	15631
@VP	used to detach the cells	15635
@VP	to detach the cells	15640
@VP	detach the cells	15643
@VP	observing detachment of elongated cells under a microscope	15696
@VP	elongated cells under a microscope	15720
@VP	were plated to new uncoated 25-cm2 flasks using the medium described earlier	15922
@VP	plated to new uncoated 25-cm2 flasks using the medium described earlier	15927
@VP	using the medium described earlier	15964
@VP	described earlier	15981
@VP	replating	16006
@VP	left for 24 h	16042
@VP	detach elongated cells , as described previously -LRB- Ito et al. , 2008 -RRB-	16090
@VP	elongated cells , as described previously -LRB- Ito et al. , 2008 -RRB-	16097
@VP	described previously	16117
@VP	was plated on new poly-L-lysine -- coated 25-cm2 flasks	16174
@VP	plated on new poly-L-lysine -- coated 25-cm2 flasks	16178
@VP	reduced from 10 % to 2.5 % over 7 days , depending on cellular growth	16318
@VP	was reached	16420
@VP	reached	16424
@VP	were plated on larger -LRB- 75 cm2 and T175 cm2 -RRB- flasks	16443
@VP	plated on larger -LRB- 75 cm2 and T175 cm2 -RRB- flasks	16448
@VP	to determine the proportion of p75 + cells and the total population number	16559
@VP	determine the proportion of p75 + cells and the total population number	16562
@VP	containing at least 2.5	16696
@VP	was ready for transplantation -LRB- between 3 and 5 weeks after harvesting -RRB-	16916
@VP	was re-anaesthetized and positioned for fluoroscopy	16997
@VP	identified previously by MRI	17325
@VP	to reach the ventral aspect of the vertebral canal	17577
@VP	reach the ventral aspect of the vertebral canal	17580
@VP	using fluoroscopy	17662
@VP	were used to ascertain correct positioning within the vertebral canal	17806
@VP	used to ascertain correct positioning within the vertebral canal	17811
@VP	to ascertain correct positioning within the vertebral canal	17816
@VP	ascertain correct positioning within the vertebral canal	17819
@VP	positioning within the vertebral canal	17837
@VP	determining their correct location within the vertebral canal	17884
@VP	injected directly into the parenchyma of the spinal cord	18334
@VP	was 400 ml in total , delivered over a period of ≈ 5 min	18413
@VP	delivered over a period of ≈ 5 min	18434
@VP	injected at the epicentre , divided into two boluses	18476
@VP	divided into two boluses	18503
@VP	directed cranially	18558
@VP	directed towards the epicentre	18709
@VP	received routine analgesia	18763
@VP	returning to the owner 's care	18852
@VP	were made at 1 , 3 and 6 months after spinal cord injection	19167
@VP	made at 1 , 3 and 6 months after spinal cord injection	19172
@VP	based on responses in a Phase	19277
@VP	suggested the need for 54 dogs in total	19338
@VP	produced a projected n = 48	19528
@VP	suggested the need for 54 dogs in total	19600
@VP	can be included	19840
@VP	be included	19844
@VP	included	19847
@VP	is readily incorporated	19960
@VP	incorporated	19971
@VP	were logarithmically transformed to normalize distributions	20190
@VP	transformed to normalize distributions	20211
@VP	to normalize distributions	20223
@VP	normalize distributions	20226
@VP	was taken as evidence to reject the null hypothesis	20661
@VP	taken as evidence to reject the null hypothesis	20665
@VP	to reject the null hypothesis	20683
@VP	reject the null hypothesis	20686
@VP	evoked potential and bladder compliance	20888
@VP	allow rigorous quantitative analysis	21009
@VP	translate into a sense of value of the effect in treated cases	21069
@VP	relate a subjective impression to the objectively measured outcome	21386
@VP	renders them unsuitable for non-verbal species	21463
@VP	can be used	21576
@VP	be used	21580
@VP	used	21583
@VP	using the formula δ = m2-m1	21661
@VP	assumed to be olfactory ensheathing cells	22004
@VP	to be olfactory ensheathing cells	22012
@VP	be olfactory ensheathing cells	22015
@VP	controlling for pre-transplant score by inclusion as a covariate	22108
@VP	to summarize patient recruitment , assessment and follow-up	22303
@VP	summarize patient recruitment , assessment and follow-up	22306
@VP	to illustrate trial design	22414
@VP	illustrate trial design	22417
@VP	had incurred severe spinal cord injury at least 3 months previously	22515
@VP	incurred severe spinal cord injury at least 3 months previously	22519
@VP	was harvested from each dog and olfactory mucosal cells	22866
@VP	harvested from each dog and olfactory mucosal cells	22870
@VP	defined as p75 + by immunocytochemistry	23057
@VP	stated here	23128
@VP	are mean ± SEM of the cell population among all 34 dogs	23140
@VP	using fluoroscopic guidance to ensure correct needle placement	23362
@VP	to ensure correct needle placement	23390
@VP	ensure correct needle placement	23393
@VP	assessed outcome at monthly intervals for 6 months after intervention	23449
@VP	was pre-specified to avoid biased analysis	23562
@VP	to avoid biased analysis	23580
@VP	avoid biased analysis	23583
@VP	biased analysis	23589
@VP	using computerized analysis of digitized kinematic data	23706
@VP	walking on a treadmill	24018
@VP	corresponding to the furthest extent of each step by each limb	24706
@VP	are only occasional stepping movements in the hindlimb	24810
@VP	stepping movements in the hindlimb	24830
@VP	shows more regular hindlimb stepping	25075
@VP	stepping	25103
@VP	is improved but imperfect	25138
@VP	is 1.21 in B	25318
@VP	interspersed with periods in which coordination between limb girdles is lost	25698
@VP	is lost	25767
@VP	lost	25770
@VP	indicate good performance	26118
@VP	controlling for the effects of time and baseline scores	26242
@VP	was highly significant -LRB- b = -0.455 ; P = 0.007 -RRB-	26299
@VP	indicate poor performance	26452
@VP	indicate linear relationships and dashed	26608
@VP	indicate linear relationships	26608
@VP	dashed	26642
@VP	indicate 95 % confidence intervals	26655
@VP	recorded before and 6 months after intervention	26753
@VP	represents a single individual	26851
@VP	represents a single individual	27207
@VP	indicate mean and SEM	27439
@VP	recorded before and 6 months after intervention	27494
@VP	indicate mean	27724
@VP	indicate SEM	27745
@VP	were assessed for eligibility for the study	27849
@VP	assessed for eligibility for the study	27854
@VP	were entered as randomized subjects -LRB- Fig. 1 -RRB-	27901
@VP	entered as randomized subjects -LRB- Fig. 1 -RRB-	27906
@VP	are typical of those affected by acute intervertebral disc extrusion	28260
@VP	affected by acute intervertebral disc extrusion	28281
@VP	presented for this study	28354
@VP	entered into the study	28670
@VP	constitutes an intention-to-treat analysis	28803
@VP	died during the study	28857
@VP	indicated no evidence to link death to the intervention	29044
@VP	to link death to the intervention	29066
@VP	link death to the intervention	29069
@VP	suspected ileus : n = 2	29163
@VP	occurred in four dogs after intraspinal transplantation	29187
@VP	was no evidence of long-term detrimental effects in any dog	29254
@VP	are summarized in Table 3	29331
@VP	summarized in Table 3	29335
@VP	is designated as a ` large effect ' -LRB- Wyrwich and Wolinshy , 2000 -RRB-	29875
@VP	designated as a ` large effect ' -LRB- Wyrwich and Wolinshy , 2000 -RRB-	29878
@VP	be expected to have an appreciable clinical benefit in human patients	29959
@VP	expected to have an appreciable clinical benefit in human patients	29962
@VP	to have an appreciable clinical benefit in human patients	29971
@VP	have an appreciable clinical benefit in human patients	29974
@VP	controlling for baseline values by inclusion as a covariate	30344
@VP	did not -LSB- b = 0.012 -LRB- 95 % CI : -0.021 to 0.046 -RRB- ; P = 0.474	30855
@VP	assumed to be olfactory ensheathing cells	31225
@VP	to be olfactory ensheathing cells	31233
@VP	be olfactory ensheathing cells	31236
@VP	to be fibroblasts derived from the sub-mucosa	31330
@VP	be fibroblasts derived from the sub-mucosa	31333
@VP	derived from the sub-mucosa	31348
@VP	-LSB- b = -0.002 -LRB- 95 % CI : -0.009 to 0.005 -RRB-	31663
@VP	could be recorded over the scalp in 12 of the 34 dogs at trial entry	32389
@VP	be recorded over the scalp in 12 of the 34 dogs at trial entry	32395
@VP	recorded over the scalp in 12 of the 34 dogs at trial entry	32398
@VP	regained	32595
@VP	had received olfactory mucosal cells	32675
@VP	received olfactory mucosal cells	32679
@VP	be recorded in the tibialis cranialis muscle before intervention in 13 dogs	32764
@VP	recorded in the tibialis cranialis muscle before intervention in 13 dogs	32767
@VP	had received olfactory mucosal cells	32935
@VP	received olfactory mucosal cells	32939
@VP	was determined in 31 dogs throughout the trial	33270
@VP	determined in 31 dogs throughout the trial	33274
@VP	described previously -RSB-	33476
@VP	randomized trial	33618
@VP	makes an effect more difficult to detect	34069
@VP	to detect	34100
@VP	detect	34103
@VP	had been paraplegic for 412 months	34273
@VP	been paraplegic for 412 months	34277
@VP	were of sufficient magnitude	34314
@VP	enrolled in the recently reported Phase	34849
@VP	can not coordinate forelimbs and hindlimbs	35148
@VP	coordinate forelimbs and hindlimbs	35155
@VP	does not necessarily imply restoration of brain control over hindlimb motion	35257
@VP	imply restoration of brain control over hindlimb motion	35278
@VP	may have exerted its effects	35463
@VP	have exerted its effects	35467
@VP	exerted its effects	35472
@VP	ensheathing cell-mediated functional improvement in complete transection models	35705
@VP	improved forelimb -- hindlimb coordination we observed	35881
@VP	observed	35924
@VP	implies enhanced communication across the damaged region of spinal cord	35933
@VP	could therefore be attributed to long-range axon regeneration	36009
@VP	be attributed to long-range axon regeneration	36025
@VP	attributed to long-range axon regeneration	36028
@VP	is more consistent with the data	36543
@VP	could result from many processes including	36592
@VP	result from many processes including	36598
@VP	including	36625
@VP	limited to , local axon sprouting	36644
@VP	sprouting	36667
@VP	may be relevant	36753
@VP	be relevant	36757
@VP	show a clear and strong overall effect of olfactory mucosal cell transplants	37266
@VP	contained within the transplant population	37454
@VP	might be quite low	37833
@VP	be quite low	37839
@VP	is not critical to the success of mucosal-derived transplants	37933
@VP	sprouting	38077
@VP	acting at a local level	38457
@VP	be useful to analyse the survival of transplanted cells within host tissue	38686
@VP	to analyse the survival of transplanted cells within host tissue	38696
@VP	analyse the survival of transplanted cells within host tissue	38699
@VP	did and did not contain cells	38908
@VP	did	38908
@VP	did not contain cells	38916
@VP	contain cells	38924
@VP	needed for blinding purposes	39040
@VP	would also be of value during translation into human patients	39186
@VP	be of value during translation into human patients	39197
@VP	ensures accurate needle placement into the spinal cord parenchyma	39369
@VP	is not necessarily more reliable in delivering cells to their target site	39439
@VP	delivering cells to their target site	39475
@VP	Obtaining cerebrospinal fluid during spinal puncture	39514
@VP	minimizing transplant leakage	39749
@VP	is simple and quick to perform	39783
@VP	to perform	39803
@VP	perform	39806
@VP	appeared to have no detrimental effects on the recipients	39815
@VP	to have no detrimental effects on the recipients	39824
@VP	have no detrimental effects on the recipients	39827
@VP	would be straightforward to translate into human medicine	39877
@VP	be straightforward to translate into human medicine	39883
@VP	to translate into human medicine	39902
@VP	translate into human medicine	39905
@VP	be of much greater relative size than the lesions treated in the current study	40149
@VP	treated in the current study	40199
@VP	carrying out this study	40248
@VP	have already carried out Phase	40503
@VP	carried out Phase	40516
@VP	demonstrating the safety of this approach	40696
@VP	will require much greater resources	40756
@VP	require much greater resources	40761
@VP	therefore needs very careful consideration	40796
@VP	allowing recovery of ` automatic ' coordination between forelimbs and hindlimbs	40965
@VP	are few data to support improvement of spinal long tract function	41050
@VP	to support improvement of spinal long tract function	41063
@VP	support improvement of spinal long tract function	41066
@VP	is able to modulate lower motor neuron activity	41307
@VP	to modulate lower motor neuron activity	41315
@VP	modulate lower motor neuron activity	41318
@VP	transplanting olfactory mucosal cells into human spinal cord injury patients	41402
@VP	would be associated with clinically detectable effects	41479
@VP	be associated with clinically detectable effects	41485
@VP	associated with clinically detectable effects	41488
@VP	would experience useful benefit in their everyday lives	41566
@VP	experience useful benefit in their everyday lives	41572
@VP	see Barnett and Riddell , 2007	41627
@VP	would provide significant clinical benefit to human spinal cord injury patients	41824
@VP	provide significant clinical benefit to human spinal cord injury patients	41830
@VP	show here	41934
@VP	be developed as a future therapeutic strategy -LRB- Thuret et al. , 2006 -RRB-	42088
@VP	developed as a future therapeutic strategy -LRB- Thuret et al. , 2006 -RRB-	42091
@VP	may have a beneficial effect on outcome	42340
@VP	have a beneficial effect on outcome	42344
@VP	may thus confound interpretation of the origin of the observed effects	42384
@VP	confound interpretation of the origin of the observed effects	42393
@VP	varied between individuals	42519
@VP	was no systematic difference between groups of transplanted and control dogs	42553
@VP	does not form an alternative explanation for our findings	42638
@VP	form an alternative explanation for our findings	42647
@VP	gained in this project	42713
@VP	providing a bridge between the laboratory and human clinic	42830
@VP	identified through previous research in rodents	42916
@VP	embarking on human trials	43025
@VP	permitting assessment using electrophysiological testing	43193
@VP	using electrophysiological testing	43215
@VP	calibrated quantitative functional neurological data	43261
@VP	drawn from this approach	43330
@VP	mediate substantial change in function in a clinical spinal cord injury model	43409
@VP	to have appreciable benefits in the treatment of human spinal cord injury	43661
@VP	have appreciable benefits in the treatment of human spinal cord injury	43664
@VP	may form a useful component of a multi-faceted approach	43753
@VP	form a useful component of a multi-faceted approach	43757
